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Mast cells have long been appreciated as the primary effector cells in allergy and 
asthma, and recently have been implicated in other inflammatory diseases. Using high 
density oligonucleotide probe arrays, we assessed genome-wide transcriptional profiles 
after Fct>RI aggregation for 90 minutes, 5 hours and 24 hours. We describe novel gene 
regulation in response to Fct>RI signaling, including altered expression of CD44, Pari, 
osteopontin, Nur77, E4BP4, and NDRG 1. In addition, the gene encoding Fct>RI � was 
downregulated 5 hours after mast cell activation according to both microarray analysis 
and RP A, and western blotting confirmed the downregulation of the beta subunit protein. 
Moreover, this downregulation of beta mRNA correlated with the decreased Fct>RI 
surface expression after mast cell activation. Very little is known about the 
transcriptional 
X 
regulation of the beta subunit of FcERI. These transcriptome profiling experiments are 
revealing novel and clinically relevant insight into how FcERI signaling may be 
controlled. 
Continuing with our focus on how mast cell activation is regulated, we examined 
the effects of Th2 cytokines on expression of important surface receptors. Murine mast 
cells co-express the activation receptor FcyRIII and the inhibitory receptor FcyRIIb and 
can be activated by lgG immune complexes. Using mouse bone marrow-derived mast 
cells, we report that IL-4 selectively increases FcyRIII expression without altering 
FcyRIIb. This enhanced expression could be induced by Stat6 activation alone, and 
appeared to be mediated in part by increased FcyRIIIa protein synthesis without 
significant changes in transcription. The increase in FcyRIII expression was functionally 
significant, as it was matched by enhanced FcyR-mediated degranulation and cytokine 
production. Selective regulation of mast cell FcyR by IL-4 could alter inflammatory lgG 
responses and subsequently disease severity and progression. Collectively, our studies 
have used genome-wide screening and reductionist studies to demonstrate mechanisms 
by which mast cell function is regulated. 
Literature Review 
Mast Cells 
In 1877, Paul Ehrlich first observed mast cells in connective tissue and termed 
them mastze/len, meaning "feeding cells", because he believed that the metachromatic 
staining granules were a result of overfeeding (Ehrlich, 1878). This reddish purple 
staining, a key identifying feature of mast cells, is due to the interaction of blue aniline 
dye with the highly acidic and abundant heparin contained within the secretory granules 
(Wills-Karp et al. 1998). 
Mast cells are the principal cellular effectors of allergic reactions and can be 
found m tissues that are exposed to the outside environment, such as beneath the 
epithelial surfaces of the respiratory tract, gastrointestinal tract, and skin. They are 
distributed throughout connective tissue and concentrated near nerves, blood and 
lymphatic vessels (Eady et al. 1979; Ryan et al. 2003). 
Mast cells originate in the bone marrow from multipotential hematopoeitic progenitors 
which progress to become unipotential mast cell committed progenitors. Although the 
exact lineage is not clear, it is known that mast cells are of myeloid lineage as determined 
by the expression of CD34+ on these progenitors. However, unlike other granulocytes, 
they do not complete their differentiation in the bone marrow. Rather, these committed 
progenitors travel through the blood stream and it is not until their arrival at the 
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connective tissues or mucosa that they differentiate and express the proteases and surface 
antigens indicative of a fully mature mast cell (Huff et al. 1988; Ashman et al. 1991; 
Rodewald et al. 1996). This differentiation and maturation is under the influence of the 
microenvironment, and the requirements differ depending on the system. In rodents both 
stem cell factor (SCF) and interleukin-3 (IL-3) are critical for mast cell maturation, but in 
human systems, only SCF is critical (Huang et al. 1990; Martin et al. 1990; Matsui et al. 
1990; Nocka et al. 1990; Tsai et al. 1991; Irani et al. 1992; Valent et al. 1992; Mitsui et 
al. 1993; Lantz et al. 1998). 
For both humans and rodents, mast cells can be divided into two distinct groups 
depending mainly on the content of their granules. In humans, mast cells are categorized 
according to their expression of proteases. Mast cells that contain tryptase alone are 
designated MCT, those that express chymase, carboxypeptidase and cathepsin G as well 
are designated MCTc (Irani et al. 1994). MCT can be found in normal lung pirmarily 
alveoli, and in the gastrointestinal mucosa, whereas MCrc are predominately located in 
normal skin, blood vessels, synovium and the gastrointestinal submucosa. However, 
these are generalizations and location is not an absolute determinant of cell type 
(Weidner et al. 1993). 
Rodents also have two distinct categories, connective tissue mast cells (CTMC) 
and mucosal mast cells (MMC). The names are misleading because like human mast 
cells, they are classified according to the contents of their granules rather than their 
location. In general, CTMC can be found in the connective tissue of skin and MMC in 
the lamina propria. One important distinguishing characteristic is the expression of 
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different proteoglycans between the two types. CTMC selectively produce heparin 
proteoglycan whereas MMC produces both heparin proteoglycan as well as chondroitin 
sulfate proteoglycans. A more precise distinguishing factor is the expression of mast cell 
specific proteases (MMCPs). Importantly, CTMC's express MMCP-5 whereas MMC 
selectively express MMCP-1 (Reynolds et al. 1990; McNeil et al. 1991 ). 
Mature mast cells regardless of type and location all express certain receptors. 
These key defining surface antigens include c-kit, a SCF receptor critical in mast cell 
proliferation and differentiation, and the high affinity lgE receptor, FcERI, the most 
appreciated receptor involved in mast cell activation. FcERI aggregation on mast cells or 
basophils, initiates a signaling cascade that results in degranulation and the release of 
lipid derived mediators, cytokines and chemokines. These events manifest as symptoms 
associated with Type IV hypersensitivity, such as local edema and swelling (wheal and 
flare), smooth-muscle contraction, vasodilation, and eventually the recruitment of other 
inflammatory cells (Schwartz 2002). 
Mast cells store pre-formed mediators such as proteoglycans, proteases, tumor 
necrosis factor alpha (TNFa) and histamine (Metcalfe et al. 1997). One paper recently 
reported that the cytokine IL-4 is also stored in human mast cells (Wilson et al. 2000). 
Histamine is a potent biogenic amine that mediates many of the immediate symptoms of 
allergy including vasodilation, bronchoconstriction, GI smooth muscle contraction and 
increased mucus production (Schwartz 2002). Shortly after degranulation is the de novo 
synthesis of lipid mediators derived from arachadonic acid, mostly the products of the 
lipoxygenase and cyclooxygenase pathways. These metabolites, namely leukotrienes 
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from the former and prostaglandins and thromboxanes from the latter pathway, can 
stimulate prolonged bronchoconstriction, enhance vascular permeability, promote 
bronchial mucus secretion, and smooth muscle contraction. Collectively, these granule 
contents and rapidly synthesized products induce the immediate phase of the Type I 
response. The late phase is characterized by the synthesis and secretion of various 
cytokines and chemokines, including IL-3, IL-4, IL-6, IL-8, IL-13, TNFa and 
MIP 1 a. This late phase is clinically discemable by prolonged inflammation, leukocyte 
recruitment, and edema (Brown et al. 1987; Young et al. 1987; Burd et al. 1989; Gordon 
et al. 1990; Gordon et al. 1991; Mecheri et al. 1997). 
It is the mast cell release of biogenically active mediators, chemokines, proteases 
and cytokines that allow them to play a central role in a variety of inflammatory 
processes including asthma, immediate and delayed hypersensitivity reactions, host 
resistance to bacterial infections, murine models of multiple sclerosis, rheumatoid 
arthritis, and inflammation in cardiovascular disease (Metcalfe et al. 1997; Galli et al. 
1999; Gommerman et al. 2000; Kelley et al. 2000; Mekori et al. 2000; Secor et al. 2000; 
Malaviya et al. 2001; Lee et al. 2002). 
Fcc;Rl, first discovered in 1970, is a multimeric cell surface receptor belonging to 
the immunoglobin receptor superfamily (Ishizaka et al. 1970; Blank et al. 1989; 
Ravetch et al. 1991). In rodents, Fcc;RI is only expressed as a tetramer (al3y2) composed 
of an alpha, beta, and two identical disulfide linked gamma subunits. Humans however 
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express FceRI as both a tetramer and a trimer (ay2) with the beta subunit being optional. 
In rodents, FceRI is limited to mast cells and basophils, but in humans, FceRI can also be 
found on eosinophils, Langerhans cells, monocytes, circulating dendritic cells and 
platelets albeit only as a trimer, and at significantly lower levels than in basophils 
(Gounni et al. 1994; Maurer et al. 1994; Maurer et al. 1996; Joseph et al. 1997; Sihra et 
al. 1997). These quantitative and qualitative differences can be accounted for by 
understanding the specific function of each receptor subunit. 
The alpha subunit is a member of the immunoglobin superfamily, with a 
relatively large extracellular domain, a transmembrane domain and a short cytoplasmic 
tail. It is the CE3 domain of this subunit that is responsible for binding the Fe portion of 
IgE, which is the primary function of this chain (Kinet 1999). 
The gamma subunit belongs to the y/8/YJ family of receptor subunits and is 
associated with the Fe receptors for IgG, IgE, and IgA, as well as with non FeR receptors 
such as paired immunoglobulin-like receptor A and natural killer cell cytotoxicity 
receptors (Maeda et al. 1998; Kubagawa et al. 1999; Moretta et al. 2001). The gamma 
subunit is found typically as a disulfide linked homodimer with a short extracellular 
domain, transmembrane domain and importantly, an intracytoplasmic domain containing 
a specific sequence called an immunoreceptor tyrosine-based activation motif (IT AM), 
which is required for signaling. It is the phosphorylation of the IT AMs found on the 
gamma that allows for the receptor to signal (Kinet 1999). 
The beta subunit, like other members of the CD20 family of molecules, has four 
transmembrane domains with both amino and carboxy termini in the cytoplasm (Kinet et 
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a!. 1988; Ra et a!. 1989). In rodent mast cells, the beta subunit associates with both 
FcERI and the low affinity Fe IgG receptor, FcyRIII, but is only required for the surface 
expression of the former (Kurosaki et a!. 1992). The beta subunit, like the gamma 
subunits, contains an IT AM within the intracellular domain, but unlike gamma, the beta 
subunit does not autonomously signal. Rather, the beta subunit serves to amplify the 
intensity of gamma signaling by a factor of five to seven, due to the beta subunit 
association with the src tyrosine kinase, lyn (Dombrowicz et a!. 1996; Lin et a!. 1996; 
Dombrowicz et a!. 1998; Kinet I 999). In addition to these functions, the beta subunit 
was also found to enhance surface expression of FcERI by promoting the processing and 
export of the alpha chain to the cell surface, as well as enhancing the stability of the 
receptor complex (Donnadieu et a!. 2000). Taking into consideration the augmented 
signaling and expression, it is estimated that the beta subunit can amplify the host 
response by a factor of 30 (Donnadieu et a!. 2000). 
Epidemiologic studies also elucidated another potentially significant role for the 
beta subunit in atopy. In pursuit of the identification of genes that could be linked to 
atopy and or bronchial hyperreactivity, an area of chromosome 11 was implicated and 
later, the region was narrowed down to the gene encoding the Fe receptor beta subunit 
(Cookson et a!. 1989; Sandford et a!. 1993). In addition, coding sequence 
polymorphisms of the beta subunit gene associated with allergic phenotypes have been 
found to be prevelant in certain populations (Shirakawa et a!. 1994; Hill et a!. 1995; 
Hill et a!. 1996; Palmer et a!. 1997; Cox et a!. 1998; Hijazi et a!. 1998). 
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Interestingly, while in search of another beta polymorphism, a short-lived 
truncated beta subunit was identified as a product of alternative gene splicing. 
Furthermore, this variant protein was found to negatively regulate surface expression of 
FcERI by competing with classical beta and preventing alpha chain maturation 
(Donnadieu et al. 2003). 
FcERI Signaling 
FcERI signaling is very similar to those of most receptors bearing ITAMs. When 
the receptor is aggregated by bound lgE capturing antigen, lyn, a src family kinase, 
becomes activated. Lyn is anchored to the cell membrane or associated with the beta 
subunit and aggregation allows for lyn to phosphorylate multiple receptors. Lyn will 
autophosphorylate and subsequently transphosphorylate the IT AM motifs found on 
Fc�;R� and FcRy. This recruits, amongst other proteins, syk, a tyrosine kinase, by its 
SH2 domain, which is in tum activated by lyn. This two step activation of lyn and syk 
initiates a signaling cascade that branches out into other signaling pathways, one 
involving the phosphorylation of phosphoinositide 3-Kinase (PBK), which leads to the 
production of phosphatidylinositol-(3,4,5)-triphosphate (Ptdlns(3,4,5)P3). 
Ptdlns(3,4,5)P3 in return recruits Tee kinases and phospholipase C gamma (PLCy) to the 
membrane by their pleckstrin-homology (PH) domains. This leads to the production of 
IP3 and diacylglycerol (DAG), causing a sustained influx of calcium (Daeron 1997; 
Ravetch et al. 2001). Ultimately this influx of calcium, along with the phosphorylation 
and activation of various other substrates such as SLP-76 and even sphingosine kinase, 
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leads to degranulation, transcription of new genes, and cytokine production (Daeron 
1997; Kinet 1999). Recent evidence also demonstrates a critical role for the src family 
kinase Fyn in regulating mast cell degranulation, although the mechanism remains 
elusive (Parravicini et al. 2002). 
FcyR 
IgG Fe Receptors can be divided into two distinct classes: activation receptors 
that contain an !TAM such as FcyRI and FcyRIII, and inhibitory receptors that bear an 
irnmunoreceptor tyrosine-based inhibitory motif (!TIM), such as FcyRIIb. Both kinds of 
receptors are widely expressed throughout the hematopoetic system, and it is the balance 
of these receptors that dictates the cellular response to the same stimuli. The high affinity 
FcyRI is found on macrophages, monocytes and neutrophils, and the low affinity FcyRIII 
on macrophages, activated monocytes, NK cells, pre-B and T cells, as well as murine 
mast cells (Daeron 1997). 
Aggregation of FcyRI or Fey Rill can mediate a variety of inflammatory processes 
depending on the cell, including degranulation, phagocytosis, antibody-dependent 
cellular cytoxicity, cytokine production, and release of inflammatory arachidonic acid 
metabolites (Daeron 1997; Ravetch et al. 200 1 ). Signal transduction through these 
receptors is almost identical to that described for FceRI. Signaling is mediated by 
!TAMs in the cytoplasmic domains of the Fe receptor y chain, through recruitment and 
activation of tyrosine�kinases such as lyn and syk. PBK is activated, eventually leading 
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to the production of IP3 and DAG causing degranulation and cytokine production 
(Ravetch et a!. 2001 ) . 
In contrast to the activation receptors, FcyRilb is a single chain low affinity 
receptor that can be expressed in different isoforms due to differential splicing. While 
ITAM sequences elicit pro-inflammatory FcyR signaling via ITAM, FcyRIIb possesses 
ITIM that preferentially interacts with Src homology 2-containing-inositol 5'­
phosphatase, or SHIP. When FcyRIIb are crosslinked with an activation receptor such as 
BCR, TCR, FcERI, FcyRI, or FcyRIII, SHIP recruitment and activation leads to the 
hydrolyzation of its primary substrate, PIP3, thereby preventing calcium influx and 
ultimately cell activation (Malbec et al. 1998; Malbec et al. 1999; Ujike et al. 1999). 
These two classes of IgG receptors are generally co-expressed on most cell types 
including monocytes, macrophages, neutrophils, and mast cells (Takizawa et al. 1992; 
Daeron 1997). In addition, both receptors bind lgG complexes with the same affinity and 
specificity, thus it is the balance of these receptors on the cell surface that will dictate the 
biological function triggered by the same stimuli. Studies where one receptor is deleted 
illustrate the importance of the regulation of the ratio of these receptors in determining 
the cellular response (Ravetch et al. 1991; Hulett et al. 1994). 
FcyRIII is a multimeric low affinity receptor consisting of an FcyRIII alpha 
subunit responsible for binding IgG complexes, and two gamma subunits responsible for 
signaling (Ravetch et al. 2001 ). Thus, mice deficient in the gamma subunit do not 
express FcyRIII nor FcERI. In studies using mice deficient in FeR gamma chain, IgG 
induced passive systemic anaphylaxis was attenuated, and this was the same for FcyRIII-
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deficient mice, indicating the capacity of lgG and FcyRIII to mediate mast cell activation 
in vivo (Hazenbos et al. 1996; Miyajima et al. 1997; Ujike et al. 1999). Surprisingly, 
mice deficient in either Fc�::RI or FcyRIIb had enhanced active anaphylaxis when induced 
by immunization with antigen and alum, but gamma deficient and FcyRIIIa deficient 
mice had an attenuated response. This unexpected result was due to the competition 
between Fc�::RI and Fey Rill for the gamma subunits. The elimination of the Fc�::RI alpha 
subunit allowed for greater surface expression of FcyRIII, tipping the balance of 
FcyRIIb/RIII towards activation of the mast cell (Dombrowicz et al. 1997). The balance 
of these receptors on mast cells also seems to play a critical role in other IgG mediated 
diseases, as recently demonstrated using a mouse model of multiple sclerosis. Mast cell 
deficient mice reconstituted with FcyRIII-/- mast cells had greatly reduced disease 
severity compared to mice reconstituted with wild type mast cells. In contrast, 
reconstitution with FcyRIIb-/- mast cells severely augmented disease pathology (Robbie­
Ryan et al. 2003). Mast cells and particularly FcyRIII expression on these cells is also 
important in murine model of rheumatoid arthritis. When serum from arthritogenic mice 
K/BxN was injected into mast cell deficient mice, the severity of rheumatoid arthritis was 
significantly reduced, and it was theorized that Fe gamma receptors could be playing a 
role, in an immune complex mediated arthus like reaction (Lee et al. 2002). In addition, 
mice that lack FcyRIII, do not develop symptoms of collagen induced arthritis, indicating 
that lgG complexes are involved in the development of this disease (Diaz de Stahl et al. 
2002). 
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Interleukin-4 
IL-4 was initially identified as a T helper cell derived cytokine that stimulated B 
cell proliferation and growth, as well as enhanced MHC class II expression (Coffman et 
al. 1986). A member of the four a-helical cytokine family, IL-4 is produced by a subset 
ofT cells, mostly T helper 2 cells but also NKI.l and y/o T cells, as well as basophils and 
mast cells (Brown et al. 1987; Seder et al. 1994; Yoshimoto et al. 1994; Chen et al. 
1997). 
IL-4 is as a critical player in controlling allergic responses and affects many 
stages of allergy. Along with its stimulatory effect on B cells, IL-4 is the principal and 
necessary cytokine that induces B cell isotype switching to lgE and lgG4 in humans and 
lgE and lgG1 in mice (Coffman et al. 1986; Gascan et al. 1991 ). In fact, in mice that lack 
either IL-4, its receptor, or the key IL-4 signaling molecule Stat6, lgE production is 
absent or greatly diminished (Kuhn et al. 1991; Kaplan et al. 1996; Shimoda et al. 1996; 
No ben-Trauth et al. 1997). Even before the production of IgE, IL-4 promotes the 
development ofT helper 2 cells from antigen stimulated naive T cells while inhibiting the 
development of T helper 1 cells, thus affecting an even earlier stage in mounting an 
allergic response (Hsieh et al. 1992; Seder et al. 1992). In accordance with its pro 
allergic role, IL-4 is a mast cell growth factor and has been shown to induce Fct::RI 
expression on in vitro-cultured human mast cells (Mosmann et al. 1986; Toru et al. 1996; 
Xia et al. 1997). 
IL-4 also affects cells other than leukocytes. Along with TNFa, IL-4 induces the 
expression of vascular cell adhesion molecule-I (VCAM-1) on vascular endothelial cells 
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and induces these cells to secrete C-C family chemokines such as monocyte chemotactic 
protein-1 (MCP-1) (Thornhill et al. 1991 ). Recently, IL-4 has also been shown to play a 
role in skeletal muscle growth by recruiting myoblasts and enhancing fusion (Horsley et 
al. 2003). 
IL-4 can mediate diverse biological functions due to the different signaling 
pathways utilized by the IL-4 receptor. There are two types of IL-4 receptor, type I and 
type II. Type I consists of two subunits, a 140 kDa IL-4Ra. chain which is a member of 
the hematopoietin receptor superfamily, and the common gamma chain (Yc) which is 
required for the activation of signaling pathways (Keegan et al. 1994 ). Type II replaces 
the Yc chain with the IL-13RI, which has many of the same properties as the former 
(Callard et al. 1996). 
The alpha chain of the IL-4 receptor has 3 different motifs with five highly 
conserved tyrosine residues critical for signaling. The most membrane proximal tyrosine, 
Y497 [Y1] is within the Insulin-IL-4 receptor (I4R) motif which generates IL-4 mediated 
proliferative signals through the recruitment and activation of Insulin receptor substrate 1 
and 2 (IRSl/2) (Keegan et al. 1994). Y2-Y4 are within the Stat-6 motif and causes the 
transcription of various IL-4 inducible genes such as CD23, MHCII, and the IL-4Ra. 
through activation of the Jak-Stat pathway (Ryan et al. 1996; Reichel et al. 1997). 
In addition to these signaling pathways, the IL-4Ra also contains a C-terminal 
ITIM that allows for interaction with phosphatases such as SH2-containing phosphatase 1 
(SHP-1) and SH2-containing inositol-5-phosphatase (SHIP) (Scharenberg et al. 1996; 
Imani et al. 1997). IL-4 signaling has also been shown to stimulate the phosphorylation 
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of SlllP, and recent studies have indicated that SHIP could positively regulate 
proliferation induced by IL-4 (Zamorano et a!. 1998; Giallourakis et al. 2000). However, 
the importance and function of the role of this phosphatase in IL-4 signaling remains to 
be fully elucidated. 
The IL-4 receptor does not have endogenous kinase activity, therefore signaling is 
dependent on associated kinases that are members of the Janus family of tyrosine kinases 
(Jak) associated with the cytokine receptor subunits. Jak1 and Jak3 are associated with 
the IL-4Ra. chain and yc chain, respectively. Upon IL-4 binding its receptor, Jak1 and 
Jak3 phosphorylate the critical tyrosine residues on the alpha chain, creating docking 
sites for different proteins, namely Stat6 and IRS1/2, by their SH2 domains (O'Shea et a!. 
2002). 
Signal transducer and activator of transcription 6 (Stat6) belongs to a family of 
molecules activated by each members of the hematopoeitin receptor superfamily and 
receptors for interferon-related molecules (Darnell 1997). After Stat6 docks the IL-4Ra 
via its SH2 domain, Jak1 and Jak3 phosphorylate Stat6. Phophorylation causes Stat6 to 
disengage from the receptor and associate with another Stat6 molecule, followed by 
translocation to the nucleus. Once in the nucleus, Stat6 recognizes a specific palindromic 
sequence, TTC-N4-GAA, and initiates transcription of IL-4 responsive genes, including 
MHCll, CD23, germline IgE, IgG 1, and IL-4Ra.. (O'Shea 1997; Nelms et a!. 1999). 
Stat6 is essential for mediating IL-4 lymphocyte responses to IL-4 and is primarily 
activated only by IL-4 (O'Shea 1997). In studies demonstrating this importance, Stat6 
deficient mice are unable to generate a Th2 response, have no IL-4 mediated upregulation 
14 
of CD23, MHCII and IL-4, and have decreased proliferation of T cells and B cells. In 
addition, B cells from Stat6 deficient mice are unable to make lgE, and T cells do not 
differentiate into Th2 cells in response to IL-4 or IL-13. After nematode infections, Stat6 
deficient cells have reduced Th2 cytokines as well as IgE and lgG l responses (Nelms et 
al. 1999). Interestingly, a mast cell specific truncated form of Stat6 has been reported. 
This Stat6 molecule is 65 kDa in size rather than the normal 94 kDa because it lacks the 
C-terminal transactivation domain. This Stat6 isoform could explain the anti­
inflammatory effects caused by IL-4 on mast cells (Sherman et al. 1999). 
IL-4 signaling also induces proliferation in cells including mast cells and B cells, 
and the IRS-l /2 pathway was found to be critical in mediating this function. Analysis of 
cell lines lacking different Jaks determined that Jak1 is critical for the phosphorylation of 
IRS 1/2. (Burfoot et al. 1997; Chen et al. 1997; Wang et al. 1997). IRS 1/2 can then 
associate with proteins that contain SH2 domains, one being the p85 subunit of PI3K. 
This recruitment activates the p 110 catalytic subunit, which phosphorylates membrane 
lipids, the most important being phosphotidylinositol-(3,4,5)-trisphosphate and PI-3,4-bP. 
These are produced within seconds of stimulation and are thought to act as second 
messenger molecules for IL-4 function. These molecules have been shown to be 
involved in the activation of Akt and PKC which lead to cell growth and survival. Other 
pathways could be potentially activated by IRS 1/2 such as the Ras!MAPK pathway but 
the literature is not yet conclusive (Nelms et al. 1999). 
MATERIALS AND METHODS 
BMMC cultures 
BMMC were maintained as primary, factor-dependent, multi-clonal populations in 
RPMI 1640 medium (Life Technologies, Grand Island, NY) supplemented with 10% 
fetal calf serum (FCS), 2mM L-glutarnine, 1 OOU/ml penicillin, 1 OOJ.!g/ml streptomycin, 
hnM sodium pyruvate, and 1mM HEPES (cRPMI; all materials from Biofluids, 
Rockville, MD), to which was added 20% volume/volume WEHI-3 cell-conditioned 
medium (cRPMIIWEHI). BMMC were cultured from bone marrow harvested from 
femurs of BL6x129 wild type, BL6x129 FcyRilu-deficient, or FcRy-deficient mice 
(Taconic farms, Germantown, NY), and maintained in cRPMIIWEHI. After 3-4 weeks in 
culture, these populations were >99% mast cells, as judged by morphology and flow 
cytometry staining for expression of FcERI, CD13, Kit, FcyRII!FcyRIII and T l /ST2 (data 
not shown). The resulting populations were generally used between weeks 4-12. 
Cytokines and reagents 
Saponin, cycloheximide, Brefeldin A, and propidium iodide were purchased from Sigma 
Imrnunochemicals (St. Louis, MO). Murine IL-3 and IL-4 were purchased from R&D 
Systems (Minneapolis, MN). P-Nitropheno-13-D-acetamido-2-deoxyglucopyranoside 
was purchased from Sigma (St. Louis, MO). 
15 
16 
Antibodies 
2.4G2 (rat anti-mouse FcyRIIIRIII), mouse IgE, FITC-conjugated rat anti-mouse CD13, 
FITC-conjugated rat anti-mouse Kit, PE-conjugated rat isotype control lgG, and FITC­
conjugated mouse-IgG were purchased from BD PharMingen (San Diego, CA). FITC­
conjugated goat F(ab'2) anti-rat lgG, and Rat anti-mouse lgE was purchased from 
Southern Biotechnology Associates (Birmingham, AL). FITC-conjugated rabbit anti­
mouse IgG was purchased from Jackson ImmunoResearch Laboratories, Inc. (West 
Grove, PA). FITC-conjugated rat anti-mouse Tl/ST2 was purchased from Morwell 
Diagnostics (Zurich, Switzerland). K9.361 anti-FcyRIIb was the kind gift of Ulrich 
Hammerling (Memorial Sloan Kettering Cancer Center, NY, NY). 
Mast Cell Activation 
BMMC were cultured at 3xl05 cells/ml in cRPMI supplemented with IL-3 
(5ng/ml) for at least 3 days. Cells were resuspended in cRPMI to a concentration of 
lxl07 cells/ml and incubated with lgE (lOug/ml) for 45 minutes at 4 C, washed twice 
with RPMI and resuspended at the same concentration in cRPMI with rat anti-IgE 
(5ug/rnl). After 40 minutes, pre-warmed cRPMIIIL-3 was added until the cells were at a 
concentration of 5xl05 cells/ml, and then incubated at 37 C for various time points. 
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Detection of sutface FcdU 
To detect FcERI surface expression, BMMC were incubated with unlabelled lgE 
(l Oj..tg/ml) for 30 minutes at 4°C, washed twice with F ACS buffer and resuspended in 
unlabelled rat anti-IgE (5 ug/ml) for 30 minutes at 4°C, washed again and finally 
resuspended in FITC-goat anti-rat lgG in the aforementioned conditions. For negative 
staining controls, lgE was omitted from the staining procedure. Cells were then washed 
twice with F ACS buffer and analyzed by F ACScan flow cytometry (Becton Dickinson 
Imrnunoctyometry, Braintree, MA) in the presence of propidium iodide to exclude dead 
cells. 
Immunoprecipitation and western blotting for FceRia 
For immunoprecipitation and western blotting of FcERia, 30 x 106 cells were 
cultured and activated as described previously, resuspended in cRPMI, pelleted and 
solubilized in ice-cold lysis buffer (0.5% Nonidet P-40, 10% glycerol; 5M NaCl; 100mM 
Tris; 1 OOmM MgClz; supplemented with an enhanced inhibitor cocktail consisting of a 
20X concentrate of Boehringer Mannheim Complete, with 80mM benzamidine HCL, 
50mM E-caproic acid, 16mM iodoacetamide, 1 Oj..tg/ml leupeptin, 1 Oj..tg/ml Pepstatin, and 
1 OOj..tg/ml soybean trypsin inhibitor) then vortexed vigorously for 15 seconds and placed 
on ice for 40 minutes. The supernatants were clarified at 14,000 x g at 4° C for 30 
minutes, aliquoted, snap frozen in liquid nitrogen, and stored at -80° C. The lysates (3 x 
107 cells/sample) were assayed (BioRad, Hercules, CA) for protein concentration 
according to the manufacturer's recommended procedure. 760 j.lg per sample were 
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immunoprecipitated using Protein A sepharose beads (50J..1l) that had been incubated 
overnight with 25J..1g of rabbit anti-mouse IgG (Jackson ImmunoResearch Laboratories) 
and either 5 J..lg of clone 5.14 anti-FcERla monoclonal antibody, or Chrompure mouse 
lgG whole (Jackson lmmunoresearch Laboratories) as a control. After 3 hours of 
incubation at 4° C, the beads with lysate were centrifuged at 4° C at 14,000 x g for 1 
minute, washed 4 times with 1 ml cold 1.0% NP-40 lysis buffer followed by one washing 
with 0.01% NP-40 lysis buffer. To recover protein, beads were boiled for five minutes 
with 40 J..ll of loading buffer (20ul BME, 20 ul of 200mM orthovanadate and 960 ul 2X 
tris-glycine sample buffer) and microfuged at 14,000 x g for 2 minutes. The supernatant 
was analyzed by SDS-PAGE on a 10% Tris-glycine gel (Invitrogen/Novex, Carlsbad, 
CA) and transferred to a nitrocellulose membrane. Membranes were blocked and 
incubated overnight at 4° C with TW anti- FcERla monoclonal antibody ( l  J..lg/ml) 
washed 4 times for 20 minutes each with 4%BSA/TTBS (lOmM Tris pH 7.2 and 150 
mM NaCl) followed by Protein A-horse radish peroxidase (Zyrned, San Francisco, CA) 
at a dilution of 1:5000. Size estimates for proteins were obtained using molecular weight 
standards from BioRad (BioRad, Hercules, CA). The reaction was developed with an 
ECL Western blotting detection kit (Amersham Life Science, Piscataway, NJ). 
Western blot for Fc&Jl.l p and FeR r 
Western blotting was performed using 50J..1g of total cellular protein. Lysates were 
boiled in 1X sample buffer and separated on either a 10% or 4-20% tris-glycine gel along 
with a molecular weight marker (BioRad, Hercules, CA). The proteins were then 
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transferred to a nitrocellulose membrane and blocked for one hour at room temperature in 
4%BSA/TTBS. Fc�:RJ� andy subunits were detected with mouse anti-Fc�:RI �(the kind 
gift of Jean-Pierre Kinet, Boston, MA) at I :2000 or rabbit anti-Fc�:RI y subunit (Upstate 
Biotechnology, Lake Placid, NY) at a I: 10 ,000 dilution, overnight at 4 ° C. Membranes 
were quick rinsed followed by washing 3 times for 20 minutes each with TTBS (IX TBS 
with 0.05% Tween-20). The secondary antibodies, rat anti-mouse lgG-horse radish 
peroxidase (Santa Cruz, Santa Cruz, CA) and by Protein A-horse radish peroxidase 
(Santa Cruz, Santa Cruz, CA) were added to fresh TTBS at a 1 :5000 dilution and 
incubated at room temperature for 1 hour. The blots were then quick rinsed again and 
washed as previously described. lrnmunoblots were then detected by ECL (Amersham 
Life Science). 
Mast Cell Activation for AffYmetrix gene chip analysis 
BMMC were cultured at 3xl05 cells/ml in cRPMI supplemented with IL-3 
(5ng/ml). After 4 days, l x l07 cells were counted, washed with RPMI, and resuspended 
in I ml of cRPMI with lgE (IOj..tg/ml) for 4 5  minutes at 4° C, washed twice with RPMI 
and resuspended at the same concentration in cRPMI with rat anti-IgE (5ug/ml). After 40 
minutes, pre-warmed cRPMIIIL-3 was added until the cells were at a concentration of 
5x 1 05 cells/ml, and then incubated at 3 7° C for either 90 minutes, 5 hours, or 24 hours, 
after which time total RNA was harvested using TRizol Reagent (InVitrogen, Carlsbad, 
CA). The RNA from these cells were compared to the RNA from a control group of mast 
cells that were incubated in cRPMVIL-3 alone for 24 hours. 
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Affymetrix gene chip analysis 
For each sample, total RNA (0.1-10 �g) was extracted from approximately 107 cells. 
RNA was harvested using TRlzol Reagent (InVitrogen, Carlsbad, CA) and further 
purified using an RNeasy Kit (Qiagen, Valencia, CA). Double stranded eDNA was 
synthesized using SuperScript Choice system (Life Technologies, Rockville, MD) and a 
T7-(dT)24 primer (Amersham Pharmacia Biotech, Buckinghamshire, England). The 
eDNA was subjected to in vitro transcription in the prescence of biotinylated nucleoside 
triphosphates using a BioArray High Yield RNA Transcript Labeling Kit (Enzo 
Diagnostics, Inc., Farmingdale, NY), based on the manufacturer's protocol. The 
biotinylated cRNA was then purified, fragmented and hybridized to Affymetrix MG­
U74A GeneChips (Santa Clara, CA) which contain approximately 6,000 full-length genes 
and 6,000 expressed sequence tags (ESTs). 
Data analysis was performed with GeneChip Analysis Suite 5.0 and Data Mining Tool 
(Affymetrix), and default settings were used. Sample loading and variations in staining 
were standardized by scaling the average of the fluorescent intensities of all genes on an 
array to a constant target intensity for all arrays. 
Average flourescence intensity was used to determine the expresswn level of an 
individual mRNA, using the following equation, (2:(PM-MM)/(number of probe pairs)), 
where PM and MM denote perfect-match and mismatch probes. This score is used to 
assess probe pair saturation and compares it to a pre-defined cut off value in order to 
determine if the gene will be called Present, Marginal or Absent. If the intensities of 
mismatched probes were very high, gene expression was judged to be absent. 
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Cells activated for 90 minutes, 5 hours and 24 hours (target samples) were 
compared to unstimulated cells cultured in IL-3 alone (reference or baseline sample) and 
Microarray Suite was used to determine if the target sample is increased, decreased or no 
change in comparison to the baseline sample. Signal log ratio quantitatively describes the 
change between the target and reference samples, and is expressed as lo� ratio. Genes 
were sorted so that only those that increased or decreased were included for further 
analysis. Of these genes, those that were scored absent in the activated sample (for 
upregulated genes) or absent in the unstimulated sample (for downregulated genes) were 
excluded. 
Hierarchical clustering 
Genes were subjected to hierarchical clustering using Cluster (Eisen, M 
[http://rana.lbl.gov/EisenSoftware.htm]). For hierarchical clustering analysis, similiarity 
was defmed based on a modified Pearsons correlation coefficient, by selecting 
Correlation uncentered in the similarity Metric dialog box. Average linkage clustering 
was then chosen to cluster the data. The results were graphically displayed using Tree 
View (Eisen, M [http://rana.lbl.gov/EisenSoftware.htm]). 
Gene Ontology analysis 
Genes were analyzed using David (Glynn Dennis Jr.) and the GoCharts module which 
uses designations assigned by the Gene Ontology Consortium 
(http://www.geneontology.org) and displays the distribution of differentially expressed 
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genes according to the different functional categories. Genes were categorized according 
to their molecular function with a coverage level of 3 out of 5, one being the least specific 
and 5 being the most specific. 
Tissue culture conditions for regulation of BMMC FcrR expression 
Cells were washed to remove WEffl-3 CM, and incubated in cRPMI at 37° C for 4-6 
hours. Cells were plated at 3x105 cells/ml, 200J.1l/well in 96-well flat-bottom plates. IL-3 
was added to 5ng/ml, followed by the indicated concentrations of IL-4. Cells were then 
incubated for the indicated times. Every 4 days half of the media and cytokines were 
replaced. FcyRIIb!RIII levels were then determined by flow cytometric analysis. 
Detection of FcyRllb and FcyRJII surface expression 
To detect FcyRIIb expression, wild type BMMC were washed with FACS buffer 
(phosphate-buffered saline (PBS)/3%FCS/0.1% sodium azide) in 96-well "V" bottom 
plates, and resuspended in unlabelled K9.361 ascites diluted 1:100, or in FACS buffer 
alone for 30 minutes at 4° C. Cells were then washed twice with F ACS buffer and 
incubated for 30 minutes at 4° C with 10J..tg/ml FITC-rabbit anti-mouse IgG, washed 
twice, and analyzed in the presence of propidium iodide to establish a live cell gate. 
Flow cytometry was performed using a Becton Dickinson F ACScan (Becton Dickinson, 
San Jose, CA). In some of these experiments, mouse IgG was employed as a control 
primary antibody in place of FACS buffer alone. To detect FcyRIII expression, FcyRIIb­
deficient BMMC were washed with F ACS buffer and incubated for 30 minutes at 4°C 
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with 1 Oj..tg/ml FITC-2.4G2, either in the presence of unlabelled 2.4G2 to serve as a 
negative control, or without unlabelled 2.4G2. Cells were then washed twice, and 
analyzed by flow cytometry in the presence of propidium iodide. We also assessed 
FcyRIIb expression by 2.4G2 staining of BMMC derived from FeR gamma chain­
deficient mice, which lack expression of FcyRlll. The percent inhibition of FcyR 
expression was calculated by comparing mean fluorescent intensities (MFI) of 
populations cultured with IL-3 alone to those cultured with IL-3 and other stimuli using 
the following equation: 
{[(MFI of IL-3 cultured BMMC)--(MFI of comparison culture)]/(MFI of IL-3 
culture)}x100. 
To detect expression of CD13, Kit, and Tl/ST2, BMMC were incubated with unlabelled 
2.4G2 ascites for 10 minutes at 4° C to block non specific binding, followed by FITC­
labeled antibodies at 10j..tg/ml for 30 minutes at 4° C. Cells were then washed twice and 
analyzed by flow cytometry in the presence of propidium iodide. 
2.4G2 Staining of fiXed and permeabilized cells 
To deteet intracellular FcyRllla. expression, FcyRIIb· deficient BMMC (3x105 
cells/ml) were washed twice with 1 X PBS and fixed with 4% paraformaldehyde/PBS for 
20 minutes at room temperature. Cells weFe washed with and resuspended in F ACS 
buffer, then stored overnight at 4° C. Cells were then resuspended in I OOj..tl of staining 
buffer (PBS, 0.1% BSA, 0.01M HEPES, and 0.5% Saponin) and incubated at room 
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temperature for 10 minutes, prior to 2.4G2 staining as described above. Samples were 
analyzed by flow cytometry using a forward scatter versus side scatter gate. 
RNase protection assay (RPA) for FcyRIII alpha and 2.4G2 crosslinkage mediated 
cytokines 
For each sample, 5x106 BMMC (cultured at 5x105 cells/ml) were starved for 4 
hours in cRPMI, then stimulated with IL-3 (5ng/ml) alone or IL-3+1L-4 (20ng/ml) for the 
indicated time points. To detect cytokine mRNA expression after 2.4G2 crosslinkage, 
cells were incubated for 10 minutes with 10!J.g/ml 2.4G2 at 4° C, washed, and incubated 
with 2.5!J.g/ml goat F(ab'2) anti-rat lgG for 90 minutes at 37° C. Total RNA was 
harvested using TRizol Reagent (InVitrogen, Carlsbad, CA) and subjected to RP A 
analysis using the RiboQuant System (PharMingen, San Diego, CA). Pixel intensity was 
determined using a Typhoon Phosphorimager 445si System equipped with ImageQuant 
software (Molecular Dynamics, Sunnyvale, CA). 
Retroviral Infection 
FcyRIIb deficient BMMC cultures were infected with retrovirus expressing a bicistronic 
construct consisting of GFP alone or GFP and the constitutively active Stat6 mutant 
termed Stat6VT as described previously (Daniel et al. 2000; Zhu et al. 2001). FcyRJII 
surface expression was assessed on the GFP-positive population by flow cytometry 
analysis using phycoerythrin-coupled 2.4G2 antibody. 
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�hexosaminidase assay 
For each sample, 6 x 104 BMMC were cultured with cytokines for the indicated 
times as described above, then stimulated by 2.402 crosslinkage in a volume of 50�-tL as 
described above for RP A measurements. The supernatant was collected 60 minutes after 
activation at 37° C and stored at -20° C. The pellet was resuspended in PBS/1% NP40, 
incubated at 0°C for 30 minutes, vortexed for 5 minutes, and clarified by centrifugation at 
10,000 RPM for 20 minutes at 4° C. P-hexosaminidase activity in cellular supernatants 
and pellets was determined as described previously (Schwartz et al. 1979). Percent 
release was calculated by dividing the amount of P-hexosaminidase activity in the 
supernatant by the sum of P-hexosaminidase activity in the supernatant and pellet. 
Specific release was determined by subtracting the percent release of unstimulated cells 
from cells stimulated by 2.402 crosslinkage. Non-specific release averages ranged from 
7.9 to 15.11 percent on day 4. 
Elisa 
For each sample, 5 x 105 BMMC were cultured for 4 days with the indicated 
cytokines in duplicate wells. Equal numbers of BMMC were then stimulated by 2.402 
crosslinkage in 200�-tL cRPMIIIL-3 for 24 hours at 37° C as described above for RPA 
measurements, with the exception that an extra wash step was included following the 
incubation with goat anti-rat IgO. Cytokine release was measured using OptEIA ELISA 
kits (BD Pharmingen, San Diego, CA). 
RESULTS 
FcdU mediated mast cell activation regulates expression of over 400 different genes at 
three separate time points. 
Mast cells have long been appreciated as the primary effector cells in allergy 
and asthma. Recently, their role in inflammation has diversified, as mast cells are now 
implicated in a variety of inflammatory processes including host resistance to bacterial 
infections, mouse models of multiple sclerosis, rheumatoid arthritis and inflammation in 
cardiovascular disease (Kelley et al. 2000; Secor et al. 2000; Malaviya et al. 2001; Lee et 
al. 2002). Mast cell activation results in the synthesis and release of many biologically 
active mediators and cytokines that can initiate, maintain or contribute to the pathology of 
the aforementioned conditions (Metcalfe et al. 1997). In order to assess changes that 
occur in gene expression after mast cell activation, bone marrow derived mast cells were 
activated by FcERI crosslinkage (IgE + anti-IgE) for 90 minutes, 5 hours and 24 hours 
and analyzed for gene expression using Affymetrix Murine Genome-U74 GeneChips. 
The GeneChips were analyzed using Microarray Suite 5.0 followed by further analysis 
with Data Mining Tool (Affymetrix). Out of over 12,000 different probe sets, 937 were 
regulated by FcERI crosslinkage in at least one time point (Figure 1). These probe sets 
were further filtered to omit expressed sequence tags, creating a list of 
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487 probe sets for known genes that are regulated by FcERI crosslinkage in at least one 
time point. (Appendix 1). To further characterize the data, remaining genes were filtered 
using Cluster (Eisen, M [http://rana.lbl.gov/EisenSoftware.htm]) to include only those 
that change at least two fold in at least two separate samples. The results were 
hierarchically clustered and depicted using Tree View (Eisen, M 
[http:/ /rana.l bl. gov /EisenSoftware.htm ]). Thus, there remained 259 probe sets 
representing known genes that either increased or decreased at least two fold after mast 
cell activation in at least two separate samples (Figure 2). 
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Figure 1. FcERl mediated mast cell activation regulates the expression of many genes. 
Bone marrow derived mast cells were incubated with IgE followed by rat anti mouse lgG 
for 90 minutes, 5 hours and 24 hours. RNA was harvested from the cell cultures and 
analyzed by Aff)rmetrix MG-U74 GeneChips. Changes in gene expression levels were 
determined by comparing activated cells to unstimulated cells, in two separate 
experiments. Results from both experiments were analyzed simultaneously. Genes were 
filtered to include only those deemed increased or decreased according to analysis by 
Microarray Suite 5.0 (Affymetrix). The remaining genes were subjected to hierarchical 
clustering and displayed graphically using Cluster and Tree View (Eisen). Each row 
represents a single gene, with each column reperesenting the mRNA levels for all of the 
genes in single treatment group of cells. Unstimulated samples were normalized to black, 
with red indicating increased expression and green indicating decreased expression 
levels. The intensity of the color reflects the degree of change, thus a darker red or green 
indicates a greater fold change over unstimulated cells. 
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Figure 2. Graphical depiction of genes subjected to hierarchical clustering using Cluster 
and Tree View. Genes that changed were filtered in Microsoft Excel to exclude 
expressed sequence tags. The remaining 487 probe sets were further filtered using 
Cluster to include only those that changed at least two fold in at least two separate time 
points (M. Eisen; [http://rana.standford.edu/software/]) and were further analyzed by 
hierarchical clustering and displayed graphical using Tree View (M. Eisen; 
[http://rana.standford.edu/software/]). 
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FcdU mediated mast cell gene expression profiles change over time. 
Mast cell activation is not an instantaneous phenomenon, but occurs in a series of 
events that manifest as symptoms both minutes and even hours later. It is well known 
that FccRI aggregation initiates a signaling cascade that results in degranulation of the 
cell within thirty minutes as well as the transcription of new genes, and that over time this 
transcriptional profile changes(Schwartz. 2002; Ryan et a!. 2003). To understand the 
changes in gene expression that occur over time, we analyzed the most changed 
transcripts at 90 minutes, 5 hours and 24 hours. After 90 minutes of activation, 174 
probe sets changed at least 2 fold or more compared to unstimulated cells. These genes 
were categorized using the Database for Annotation, Visualization and Integrated 
Discovery (DAVID). This program utilizes various databases to annotate and chart 
different gene lists into chosen specified categories (Glynn Dennis Jr. 2003). In order to 
get a global overview of the changes occurring after ninety minutes of activation, the 
genes were categorized according to molecular function using vocabulary from the gene 
ontology consortium (GO analysis). 21.3% of the 174 genes are involved in DNA 
binding. When these genes were further categorized according to biological function, 
75.7% of these DNA binding genes were involved in transcription or the regulation of 
transcription with 24.9% of these genes involved in regulation of the cell cycle. 10.9% of 
the genes transcribed at ninety minutes are involved in purine nucleotide binding, 42.1% 
of these involved in phosphorylation and 31.6% consisted of genes involved in small 
GTPase mediated signal transduction. The third and fourth largest category of genes 
were those involved in cytokine activity and growth factor activity, 9.2% and 5. 7% 
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respectively. These categories consisted of primarily all the inflammatory cytokines (i.e. 
interleukin-13), growth factors (i.e. GM-CSF) and chemokines such as MIP1a (Figure 3). 
The most upregulated and downregulated transcripts after ninety minutes are 
presented in table format. Not surprisingly, 6 of the 10 most upregulated genes are 
chemokines, inflammatory cytokines and growth factors such as Interleukin-13, 
prostaglandin-endopoeroxide synthase 2 (COX-2) and GM-CSF, and the other four are 
involved in cell signaling. The top three transcripts, chemokine (C-C motif) ligand 7 
(MCP-3), CCL-4 (MIP1 beta) and CCL-3 (MIP1 alpha) increased 502, 179, and 169 fold 
respectively. These results are in agreement with a previously published paper reporting 
these chemokines as the most upregulated transcripts after mast cell activation. 
(Nakajima et al. 2002). Interestingly, one of the signaling molecules transcribed, early 
growth response 2, a transcription factor induced by inflammatory stimuli, was 
upregulated 72 fold over unactivated cells. The ten most downregulated genes at ninety 
minutes are involved in cell signaling, cell cycle regulation, or chromatin packaging. 
One, schlafen 2, has been reported to be involved in the supression ofT cell growth but 
the presence or role of this protein in mast cells has not been reported (Schwarz et al. 
1998). (Table 1 ). 
Five hours after mast cell activation, 202 probe sets are described to change at 
least two fold compared to unstimulated cells, compared to the 174 genes regulated at 
ninety minutes. After analysis with DAVID and GOChart, the top three categories were 
similar, with 16.8% of genes involved in DNA binding, 15.3% in purine nucleotide 
binding, and 8.4% involved in transferase activity (Figure 4). Of the genes categorized as 
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DNA binding, the majority function in the regulation of transcription ( 73.5%) with cell 
cycle regulation and DNA replication a far second and third ( 20.6% and 17.6% 
respectively). The most changed transcripts at five hours however differed from those 
seen at 90 minutes. The two most abundantly transcribed genes compared to 
unstimulated cells were again chemokines, however, the fold change was reduced to 59 
fold over baseline, compared to 502 fold at ninety minutes (Table 2). Interestingly, the 
third most increased transcript at five hours is secreted phosphoprotein 1, better known as 
osteopontin. Osteopontin contributes to the development ofT helper 1 immunity, and is 
implicated in a wide assortment of inflammatory diseases including experimental 
autoimmune encephalomyelitis (Jansson et al. 2002). Its role in mast cells has yet to be 
reported. Further, a known receptor for a breakdown product of osteopontin, CD44 is the 
ninth most increased transcript five hours after mast cell activation. This surface antigen 
also binds hyaluronic acid and has been implicated in other diseases including allergic 
lung inflammation. (Teder et al. 2002; Katoh et al. 2003). Its expression has been 
reported on human mast cells, but there is little literature suggesting a role for this 
receptor in mast cell-mediated disease (Kruger-Krasagakes et al. 1996). 
Transcriptional activity has significantly slowed down 24 hours after the initial 
Fct::Rl mediated activation of the mast cell. Only 69 genes change 2 fold or more, with 
the top three categories again being DNA binding ( 13%), purine nucleotide binding 
( 11.6% ), and cytokine activity (8. 7) (Figure 5). The vast majority of DNA binding genes 
function in the regulation of transcription, and the majority of purine nucleotide binding 
genes are important in phosphorylation. The most increased transcript, procollagen, type 
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XVIll, alpha 1, also known as endostatin, is a potent anti-angiogenic factor (Table 3) 
(O'Reilly et al. 1997; Dhanabal et al. 1999). This transcript increases a modest 10 fold, 
compared to the most increased transcript at 90 minutes, CCL7, which increased a 
tremendous 502 fold compared to unstimulated cells. Another gene regulated at this 
time point, Nuclear factor, interleukin 3 regulated (E4BP4), is a transcription factor 
known to be up regulated by IL-3. It has been recently published that in Ba!F3 cells, IL-
3 regulates the expression of E4BP4 through GATA1, and that this is important in IL-3 
mediated survival and anti-apoptotic signaling (Yu et al. 2002). Although this gene is 
upregulated both 90 minutes and 5 hours after mast cell activation (7 fold and 3 fold 
respectively), by 24 hours, the gene coding for E4BP4 is the second most downregulated 
gene at this time point, at about 4 fold below unstimulated cells (Table 3). 
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Figure 3. Probe sets that increased or decreased at least two fold after ninety minutes of 
FccRI crosslinkage were analyzed using the Database for Annotation, Visualization and 
Integrated Discover (David). The 174 probe sets were categorized according to their 
functional categories using the vocabulary given by the Gene Ontology Consortium (GO) 
and displayed in graphical format. Ninety-eight of the 174 probe sets listed (43.7%) 
were unclassified and not represented graphically. 
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Table 1. Top 20 most changed genes 90 minutes after FcERI aggregation. 
Probe m Gene Name Gene Symbol Average Fold Change 
90 mios Shrs 24 hrs 
94761_at chemokine (C-C motif) ligand 7 (MCP-3) Ccl7 502.70 55.98 4.80 
94146_at chemokine (C-C motif) ligand 4 (MJPI beta) Ccl4 179.45 11.28 1.13 
102424_at chemokine (C-C motif) ligand 3 (MJPI alpha) Ccl3 168.87 59.04 3.08 
94168_at interleukin 13 1 13 95.52 18.27 -0.05 
104647_at prostaglandin-endoperoxide synthase 2 (COX-2) Ptgs2 93.16 1.80 -1.12 
102661_at early growth response 2 Egr2 72.53 1.81 -1.65 
92948_at colony stimulating fuctor 2 (granulocyte-macrophage) Csf2 68.07 0.08 -0.10 
102780_at neoplastic progression 3 Npn3 62.79 11.95 0.63 
104155_f_at activating transcription factor 3 AtG 46.15 1.51 -1.30 
92356 at protein tyrosine phosphatase, non-receptor type 8 Ptpn8 40.28 8.13 -1.06 
102318_at sialyltransfcrase 8 (alpha-2, 8-sialyltransfcrasc) D Siat8d -9.91 -8.09 -0.25 
98010_at nuclear factor, erythroid derived 2 Nfc2 -7.34 -6.98 -0.02 
102397_at core-binding factor. runt domain. alpha subunit 2: translocated to, 3 homolog (human) Cbfa2t3h -7.25 -4.72 1.05 
92472_f_at schlafen 2 Slfu2 -6.02 -175 1.40 
92409_at zinc finger protein 260 Zfp260 -4.18 -4.59 -0.72 
103342_at embryonic ectoderm development Eed -4.12 -1.24 -1.09 
93414_at AlP-binding cassette, sulrfamily B (MDR!TAP), member lB Abcb l b  -3.97 -5.49 1.08 
93697_at chromobox homolog 4 (Drosophila Pc class) Cbx4 -3.50 -2.64 -1.55 
9247l _i_at schlafen 2 Slfn2 -3.34 -179 1.56 
103346_at CDC-like kinase 2 Clk2 -3.02 -1.58 -1.08 
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Figure 4. Probe sets that increased or decreased at least two fold after 5 hours of FceRI 
crosslinkage were analyzed using the Database for Annotation, Visualization and 
Integrated Discover (David). The 202 probe sets were categorized according to their 
functional categories using the vocabulary given by the Gene Ontology Consortium (GO) 
and displayed in graphical format. One hundred twenty five of the 202 probe sets listed 
(38.1 %) were unclassified and not represented graphically. 
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Table 2. Top 20 most changed genes 5 hours after FcERI aggregation. 
Probe lD Gene Name Gene Srmbol Avenge Fold Change 
90 mins Shrs 24 hrs 
102424_at ch emokin e (C-C motif) ligand 3 (MIPI alpha) Ccl3 168.87 59.04 3.08 
94761_at chemokine (C-C motif) ligand 7 (MCP-3) Ccl7 502.70 55.98 4.80 
97519_at secreted phosphoprotein I (osteopontin) Sppl 11.95 29.72 2.52 
93328_at histidine d ecarboxylase Hdc 2 1.56 29.13 2.48 
101881_g_at procollagen, type XVlll, alpha I (endostatin) Coll8al -I 25 25.28 10.55 
100127_at cellular r etinoic acid binding protein II Crabp2 7.71 23.95 -4 61 
93930_at LIM and SH3 protein I Laspl 11.67 22.05 6.61 
94168_at int erleukin 13 1113 95.52 18.27 -0 05 
AFFX-TransRecMur/X57349 _ M _at transferrin rec eptor Trfr 7.97 15.08 -0.12 
103005_s_at CD44 antigen Cd44 15.06 14.69 2.02 
102806 � at CEA-related c ell adhesion molecule I Ceacaml 5.87 12.47 3.27 
95364_at guanine nucleotide binding protein . alpha 14 Gnal 4 -2.17 -13.93 0.11 
99457 _at antigen id entified by monoclonal antibody Ki 67 Mki67 -2.04 -12.57 -3 II 
103468 at meiosis-spec ific nuclear structural protein I Mnsl -2.12 -9.39 -1 29 
104333_at G7e protein G 7c-pending -2.05 -8 53 -2.19 
102337_s_at Fe receptor, l gG. low affinity Jib Fcgr2b -1.65 -8.35 -0.51 
102318_at s•1lyltransferase 8 (alpha-2. 8-sia1yltransferase) I) Siat8d -9 .91 -8.09 -0.25 
97421_at SMC2 structural maintenance of chromosomes 2-likc I (yeast) Smc211 -1.41 -7.89 -1.96 
98010 at nuclear factor. erythroid derived 2 Nfe2 -7.34 -6.98 -0.02 
42 
Figure 5. Probe sets that increased or decreased at least two fold after 24 hours ofFcERl 
crosslinkage were analyzed using the Database for Annotation, Visualization and 
Integrated Discover (David). The 69 probe sets were categorized according to their 
functional categories using the vocabulary given by the Gene Ontology Consortium (GO) 
and displayed in graphical format. Twenty-nine of the 69 probe sets listed (58.0%) were 
unclassified and not represented graphically. 
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Table 3. Top 20 most changed genes 24 hours after FcERI aggregation. 
Gene Name Gene Symbol Average Fold Oumge 
90 mins Shrs 24hrs 
procollagen, type XVJII, alprn I (Endlstatin) Coli Sal -125 25.28 10.55 
LIM and Sl-13 protein I Laspl 11.67 22.05 6.61 
acidic epididyrml gl)mprotein I Aegl 0.11 2.36 6.17 
futty acid-Coenzyme A ligase, long cffiin 4 Facl4 8.72 10.83 6.06 
cll:nukine (C-C rrotiO lig<nl 7 (M'Y-3) Ccl7 502.70 55.98 4.80 
RAB4A, rrerrixT RAS orrogene furrily Rab4a 6.56 8.42 4.47 
CD68 antigen Ql68 -0.09 2.09 4.25 
turror necrosis fuctor, alpha-ir;.:luced protein 3 Tnfuip3 1.91 7.76 3.95 
hoTWJdormin intt:rocting protein ki= I Hipkl 35.53 10.46 3.95 
paired-lg-like receptor A3 Pira3 1.44 0.80 3.74 
cytoplasrric tyrosin: ki=, D!n28C related Tee 5.78 6.04 3.70 
cellular retiooic acid binding protein II Oal;p2 7.71 23.95 -4.61 
noclear fuctor, interleukin 3, regulated (E41-.p4) Nfil3 6.90 2.58 -3.87 
COC28 protein kirnsc I Cksl -1.14 -1.99 -3.39 
scrirr/thrconine kimse 6 Stk6 -1.92 -5.38 -3.38 
antigen iOOltified by rronoclonal antibody Ki 67 Mki67 -2.04 -12.57 -3.11 
MAD2 (tritotic arrest defJCient, oorrolog)-like I (yeast) tvlad211 -1.55 -2.37 -3.10 
plnsphoglycerate kimse I Pgkl 0.24 0.33 -2.92 
proviral integration site 2 Pim2 -1.36 -3.68 -2.77 
kinesin farrily rrerrixT II Kifl l -1.76 -2.90 -2.74 
solute carrier family 7 (cationic an�m acid transporter. y+ system). rrerrtx:r 5 Slc7a5 2.74 2.63 -2.72 
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Mast Cell Activation regulates the expression of genes involved in cell signaling. 
Probe sets of interest were selected and categorized into four groups, genes 
involved in signaling, cell cycle and/or apoptosis, immune response, and surface 
antigens. Thirty-two cell signaling genes were listed in table format, analyzed by 
hierarchical clustering, and also graphically represented using Tree View (Figure 6 and 
Table 4). Of the 32 genes listed, only nine genes consistently decrease over the three 
time points, including GAT A2, a transcription factor that is required for the early 
differentiation of mast cells from progenitors (Tsai et al. I997). 
As would be expected, many genes involved in early signaling events are 
upregulated at 90 minutes. Almost immediately after FcERI aggregation, the gene for 
activating transcription factor 3 (ATF3) is upregulated 40 fold. This gene is a member of 
the basic region leucine zipper family of transcription factors and is known to be 
upregulated in many tissues as an immediate response gene to stress and damage (Hai et 
al. 200I). Fyn, another member of this family, recently found to be critical for mast cell 
degraulation, is regulated by mast cell activation (Parravicini et al. 2002). Transcription 
factors are also regulated, such as FosB and JunD, members of the AP-I transcription 
family, which are upregulated at 90 minutes (Table 4). Moreover, genes thought to 
inhibit signaling are also upregulated 90 minutes after m;;tSt cell activation, such as 
SOCS3 and CIS. One noteworthy gene that is upregulated after mast cell activation is the 
nuclear receptor subfamily 4, group A, member I (Nurr77). This protein is a member of 
the orphan nuclear receptor family, and the message for it increased an average of 38 fold 
90 minutes after mast cell activation. Nurr77 protein has been shown to play a role in 
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TCR mediated cell death and thymocyte negative selection, as well as death in 
macrophages (He 2002; Kim et al. 2003). Its induction after mast cell activation has not 
been reported and could warrant further study. 
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Figure 6. Graphical depiction of selected genes important in cell signaling and regulated 
by FcERI crosslinkage. Selected genes were analyzed and subjected to hierarchical 
clustering using Cluster and displayed graphically using Tree View. Both independent 
experiments are depicted in the same graph. 
l.f>lb 
serine/threonine kinase 10 
CDC-like kinase 2 
Chromobox homolog 4 
GATA2 
nuclear factor, erythroid derived 2 
Ptnn2 
Pn� 
Ezh2 (mEmr-1) 
Hink2 
ATF4 
ATF3 
Ncrfi-A binding protein 2 
E4bn4 
SOCS3 
JunD1 
rhoB 
Nr4a2 1Nurr1) 
Cebn beta 
N-mvc 
reatllator of G-protein signaling 2 
l-fadh7 1Smad7) 
Teicr1 lmGIFl 
Nr4a2 (Nurr1) 
FosB 
l-fan2K3 (HEK3) 
DUB2 
CIS 
dual snecificity phosphatase 1 
Nr4a1 1Nur77) 
Tee Kinase 
F2r (Par1) 
48 
49 
Table 4. Cell Signaling Genes regulated by FcERI aggregation. 
Name/Description Identifier Fold change 
90 mins Shrs 24 hrs 
ATF3 104156 r at 39.09 0.54 0.34 
ATF4 100599 at 2.47 0.1 -1.71 
Cebp beta 92925 at 6.59 1.91 -1.18 
CIS 100022 at 3 1.99 0.2 
dual specificity phosphatase 1 104598 at 26.76 2.63 1.63 
DUB2 99905 at 15.36 5.22 3.16 
E4bp4 102955 at 6.9 2.58 -3.87 
F2r (Pari) 92356 at 40.28 8.13 -1.06 
FosB 103990 at 12.96 -0.1 -1.34 
Fyn proto-oncogene 100133 at 1.87 4.09 1.15 
Hipk2 103833 at -1.03 8.29 -0.03 
JunDt 102364 at 2.97 1.3 I. II 
Madh7 (Smad7) 92216 at 5.53 0.85 1.21 
Map2K3 (MEK3) 93314_g_at 2.4 2.39 -0.89 
Ngfi-A binding protein 2 100962 at 12.49 2.54 -1.21 
N-myc 103048 at 4.12 1.22 1.4 
Nr4a1 (Nur77) 102371 at 37.89 -1.78 2.54 
Nr4a2 (Nurrl) 92248 at 31.69 2.22 1.13 
Nr4a2 (Nurr 1) 92249_g_at 15.58 2.22 1.59 
regulator of G-protein signaling 2 97844 at 12.87 2.62 1.12 
RhoB 101030 at 6.12 2.39 1.34 
SOCS3 92232 at 12.37 0.12 3.7 
Tee Kinase 103539 at 5.78 6.04 1.08 
Tiegl (mGIF) 99603 g at 5.96 3.25 1.20 
CDC-like kinase 2 I 03346 at -3.02 -I.58 -1.08 
chromobox homolog 4 93697 at -3.5 -2.64 -1.55 
Ezh2 (mEnx-1) 99917 at -1.48 -2.62 -1.76 
GATA2 I 02789 at -2.7 -1.31 -I. II 
Myb 92644 s at -2.81 -0.07 1.05 
nuclear factor, erythroid derived 2 98010 at -7.34 -6.98 -0.02 
PIM2 10I926 at -1.36 -3.68 -2.77 
Ptpn2 I 01996 at -1.86 -4.99 -1.8 
serine/threonine kinase I 0 93680 at -2.51 -1.74 -0.03 
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Mast cell activation regulates the expression of cell cycle and apoptosis involved genes. 
Cell cycle and apoptosis regulation are important in the ability of the mast cell to 
maintain an inflammatory response. In order to gain insight into the role of mast cell 
activation in cell cycle regulation, we selected genes known to be involved in cell cycle 
regulation and apoptosis for further study. Cyclin 3, cyclin B2, cyclin 02, and 
retinoblastoma gene are all downregulated at 90 minutes, 5 hours and 24 hours, between 
one fold and three fold. Cyclin D2 however, is modestly upregulated at 5 hours and 24 
hours. Concomittantly, p21, a cyclin dependent kinase inhibitor, is upregulated almost 5 
fold at 90 minutes. However, in contrast, p 19, cyclin dependendent kinase inhibitor of 
CDK4, is downregulated almost 7 fold at 5 hours. 
One interesting gene involved in cell cycling, N-myc downstream regulated 1, or 
NDRG 1, is a serine protease recently characterized to be highly expressed in mast cells 
cultured in stem cell factor. This protein has been theorized to be responsible for mast 
cell maturation, allowing for degranulation to stimuli (Taketomi et a!. 2003). Our 
microarray analysis revealed that 90 minutes after mast cell activation, this gene is 
upregulated almost 13 fold and is back to baseline by 24 hours. (Figure 7, Table 5). 
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Figure 7. Graphical depiction of selected genes important in cell cycling and apoptosis 
and regulated by Fc�::RI crosslinkage. Selected regulated genes were analyzed and 
subjected to hierarchical clustering using Cluster and displayed graphically using Tree 
View. Both independent experiments are depicted in one graph. 
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Table 5. Selected genes important in cell cycle and survival. 
Name/Description Identifier Fold change 
90 mins Shrs 24 hrs 
Btg1 93104 at 4.53 2.89 1.90 
cyclin 02 97504 at -0.25 2.36 1.60 
ecotropic viral integration site 2 98025 at 4.98 1.41 2.38 
epithelial membrane protein I 97426 at 23.55 8.57 2.53 
lgtbp5 100566 at -1.32 2.33 1.57 
Myd116 160463 at 3.37 1.50 1.25 
Ndr l 96596 at 12.56 4.94 0.04 
Nedd9 101469 at 5.92 2.01 0.14 
N-myc downstream regulated I 160464 s at 12.81 4.67 0.05 
p21 98067 at 4.23 1.71 0.04 
tnfaip3 99392 at 1.91 7.76 3.95 
Bid 98433 at -2.84 -1.75 1.22 
Bnip31 (nix) 96255 at 0.20 -6.40 0.17 
Cdc2a 100128 at -1.38 -2.50 -2.47 
cyclin 3 160545 at -1.75 -2.02 -0.02 
cyclin 82 94294 at -1.02 -2.39 -2.20 
cyclin G2 98478 at -2.49 -3.25 -0.08 
Mad2 99632 at -1.55 -2.37 -3.10 
Mki67 99457 at -2.04 -12.57 -3.11 
Ndst2 92400 at -2.62 -2.80 1.09 
nuclear protein 95 99564 at -1.576 -4.20 -1.87 
p19 94521 at -1.37 -6.70 -2.12 
Parp2 100903 at -2.51 -1.58 -1.22 
polymerase (DNA directed), alpha 1 103207 at -1.39 -2.53 -0.43 
Rb1 97948 at -1.298 -2.68 -0.10 
ribonucleotide reductase M I 100612 at -1.64 -5.05 -2.42 
schlafen 2 92472 f at -6.02 -1.75 1.40 
serine/threonine kinase 6 92639 at -1.92 -5.38 -3.38 
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Mast cell activation strongly regulates genes involved in the inflammatory response. 
Activation of the mast cell through FcERI results in the new synthesis of 
cytokines, chemokines, and growth factors. This process has been highly studied, 
especially in the context of mast cell mediated disease. (Plaut et al. 1989; Galli et al. 
1993; Bradding et al. 1996; Lane et al. 1996; Metcalfe et al. 1997). As would be 
expected, we also found by microarray analysis a rapid and strong induction of pro­
inflammatory molecules after 90 minutes of FcERI aggregation, including chemokines, 
inflammatory cytokines and growth factors. As previously mentioned, the top 3 most 
increased transcripts at ninety minutes are chemokines CCL7, CCL4, and CCL3. It is 
also not surprising that the 41h most increased transcript at ninety minutes is the 
inflammatory cytokine Interleukin-13, which has many overlapping functions with 
Interleukin-4 and plays a significant role in the progression and severity of asthma 
(Wills-Karp et al. 1998). Mast cell activation also upregulates certain enzymes involved 
in the process of manufacturing more inflammatory mediators such as histidine 
decarboxylase and COX-2. Another pro-inflammatory protein, Activin A, was 
transcriptionally upregulated 4 fold at 90 minutes in our analysis. This confirms a 
previous report demonstrating the induction of activin PA transcription in mast cells after 
activation with PMA and the calcium ionophore A23187, and that this protein promoted 
the proliferation of human airway smooth muscle cells (Cho et al. 2003) (Figure 8, Table 
6). 
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Figure 8. Graphical depiction of selected immune response genes and regulated by 
FcERI aggregation. Selected genes were analzyed and subjected to hierarchical clustering 
using Cluster and displayed graphically using Tree View. Both independent experiments 
are depicted in one graph. 
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Table 6. Table of selected immune response genes regulated by FcERI aggregation. 
Name/Descri�tion Identifier Fold Change 
90 mins Shrs 24 hrs 
CCLI 94166_g_at 4.98 4.34 -1.62 
CCL2 (MCPI) 102736 at 10.44 0.17 0.13 
CCL3 (MIP I alpha) 102424 at 168.87 59.04 3.08 
CCL4 (MIPI beta) 94146 at 179.45 11.28 1.13 
CCL 7 (MCP-3) 94761 at 502.70 55.98 4.80 
CCL9 (MRP-2) 104388 at 1.71 2.60 2.32 
COX-2 I 04647 at 93.16 1.80 -1.12 
Diphtheria toxin receptor (HB-EGF) 92730 at 31.80 3.97 0.80 
GMCSF 92948 at 68.07 0.08 -0.10 
histidine decarboxylase 93328 at 21.56 29.13 2.48 
IL-l beta 103486 at 11.89 7.08 1.68 
IL-13 94168 at 95.52 18.27 -0.05 
IL-4 92283 s at 15.23 1.74 1.04 
IL-6 102218 at 14.27 3.26 0.08 
lNF beta 160092 at 10.44 1.51 0.50 
inhibin beta-A (activin A) I 00277 at 3.80 0.22 0.19 
MCSF 101450 at 19.05 4.82 2.51 
PDGF alpha 94932 at 2.98 7.12 2.88 
SAM domain and HD domain, I I 03080 at 3.10 0.12 1.75 
secreted phosphoprotein I 97519 at 11.95 29.72 2.52 
TGF beta I 101918 at 1.56 2.31 1.19 
TNF 102629 at 16.99 2.99 0.80 
TNFL superfamily 8 (CD I 53) 101136 at 5.51 1.34 0.46 
TNFL superfamily 9 (4IBB ligand) 92415 at 3.44 -0.01 1.36 
YEGFa I 03520 at 4.00 1.42 -0.83 
CD8 beta 94000 at -2.17 -4.98 -0.32 
Siat8d I 02318 at -9.91 -8.09 -0.25 
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Mast cell activation modulates the transcription of cell surface antigen genes. 
It is reasonable to assume that mast cell activation would initiate a cascade that 
would ultimately alter the ability of the cell to undergo further stimulation, and one 
method could be through the regulation of its surface antigens. The most strongly 
induced surface receptor is the hyaluronic acid receptor CD44. Recent studies have 
implicated its role in both mediating inflammation as well as resolving it (Teder et a!. 
2002; Katoh et a!. 2003). However, its role in mast cell function has not been fully 
elucidated and could be worth further study. The most downregulated surface receptor 
after mast cell activation is the inhibitory low affinity lgG receptor, FcyRIIb. (Figure 9, 
Table 7). Dysregulation of FcyRIIb expression or signaling can lead to the susceptibility 
of many autoimmune diseases including SLE, EAE and rheumatoid arthritis (Clynes et a!. 
1998; Johansson et a!. 2001; Robbie-Ryan et a!. 2003). The regulation of FcyRIIb by 
mast cell activation could be of importance in the role of the mast cell in these diseases 
(Ravetch et a!. 2001 ) . 
Also of interest is coagulation factor II (thrombin) receptor, or F2r, or Pari. It 
has previously been reported that thrombin can activate mast cells causing degranulation, 
cytokine release and mast cell adherence to fibronectin (Vliagoftis 2002). We found by 
microarray analysis that the transcription of Pari increased 2.8 fold, 4.62 fold and 3.14 
fold over 90 minutes, 5 hours and 24 hours after activation. 
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Figure 9. Graphical depiction of surface antigen genes regulated by FceRI crosslinkage. 
Selected regulated genes were analyzed and subjected to hierarchical clustering using 
Cluster and displayed graphically using Tree View. Both independent experiments are 
depicted in one graph. 
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Table 7. Table of selected surface antigen genes. 
Name/Description Identifier Fold Change 
90 mins Shrs 24 hrs 
CCR1 99413 at 3.98 1.52 0.24 
CD44 103005 s at 15.06 14.69 2.02 
CD 53 94939 at 2.05 3.14 1.62 
CD68 103016 s at -0.09 2.09 4.25 
CD9 95661 at 1.83 2.47 1.67 
F2R (PARI) 92267 at 2.797 4.62 3.14 
IL-17R 99991 at 2.34 -0.24 1.29 
IL-3Rb (GM-CSFR2b1) 94748_g_at -0.11 1.74 2.11 
IL-3Rb (GM-CSFR2bl) 94747 at -1.37 1.44 1.74 
Lasp1 93930 at 11.67 22.05 6.61 
PIRA3 100328 s at 1.44 0.80 3.74 
PIRB 98003 at 0.00 1.16 2.41 
CD48 103089 at -1.57 -2.34 -1.14 
c-kit 99956 at -1.47 -1.41 1.36 
Fe gamma Rllb 102337 s at -1.65 -8.35 -0.51 
FceRI alpha 101209 at -1.15 -1.27 1.15 
FceRI beta 96509 at -0.28 -4.29 1.80 
IL-18Rl 101144 at -2.29 -2.62 0.37 
IL-4R alpha 102021 at -2.22 -1.41 0.09 
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Mast cell activation regulates the transcription of the Fc&RJ beta subunit. 
We found that levels ofFcERI alpha and gamma transcripts were not significantly 
altered after mast cell activation. However, the level of the beta subunit, shared by both 
FcERI and FcyRITI, was reduced 4 fold after five hours of mast cell activation compared 
to unstimulated cells. The beta subunit is critical for FcERI expression in rodents, and 
although not required for human FcERI expression, can augment both its signaling and 
expression (Dombrowicz et a!. 1998; Donnadieu et a!. 2000). Besides the recent fmding 
that GAT A-1 binds the beta chain promoter, little else is known about events that 
regulate its transcription and expression (Maeda et a!. 2003). Thus our finding by 
GeneChip analysis that mast cell activation could potentially regulate the transcription of 
the beta chain was of great interest. 
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Ribonuclease Protection Assay confirms GeneChip results. 
To confirm our microarray results, we analyzed mRNA levels of various 
cytokines and Fe receptor subunits by ribonuclease protection assay. BMMC were 
incubated in IL-3 and activated by FceRI crosslinkage (IgE+anti-IgE) for ninety minutes, 
5 hours and 24 hours, after which RNA was harvested and subjected to RP A analysis. In 
accordance with the microarray analysis, there was an upregulation of IL-13, IL-6 and 
TNFa message levels ninety minutes after activation (Figure 10 and Figure 11). 
The mRNA levels of FcERI subunits were also assessed by RP A using IgE crosslinkage 
or pharmacolocial activation with the calcium ionophore, ionomycin (Figure 12). In 
agreement with the results from GeneChip analysis, 5 hours after activation, the FcERI 
alpha subunit does not significantly change after FceRI crosslinkage (Figure 13). The 
gamma subunit on the other hand is significantly reduced after 5 hours of crosslinkage 
(Figure 14). This experiment has been repeated and because of inconsistent results needs 
to be further studied. Importantly, FceRI� message levels are reduced by almost 80 
percent compared to unstimulated cells 5 hours after mast cell activation, and this result 
has remained consistent throughout 5 separate experiments (Figure 15). 
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Figure 10. RP A analysis confirming upregulation of cytokines after mast cell activation. 
Wild type BMMC were cultured in IgE followed by rat anti-mouse IgG for 90 minutes 
and 5 hours, or were left unstimulated. 
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Figure 11. Summary of percent change in mRNA levels ofTNFa, IL-6, and IL-13 in 
cells activated for 90 minutes and 5 hours, compared to unstimulated cells. 
Phosphorimaging was used to determine the ratio of cytokine expression to the 
expression of L32+GAPDH for each sample. 
66 
67 
80 
riJ. • TNF alpha 
� 
= • IL-6 � 
� 
60 • IL-13 
eiJ 
= 
·-
c. 
� 
40 � 
� 
� 
riJ. 
= 
0 
= 
20 
� 
0 
� 
= 
0 
unstimulated IgE + a.E IgE + a.E 
90 mins 5 hours 
Figure 12. RP A demonstrates the different levels of FceRI a, !3 and y subunits after 
FcERI mediated mast cell activation. Wild type BMMC were cultured in either lgE 
followed by rat anti-mouse lgG, or ionomycin for 5 hours, or were left unstimulated. 
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Figure 13. Percent change ofFcERI a mRNA in cells activated by FcERI aggregation or 
ionomycin for 5 hours and compared to unstimulated cells. Phosphorimaging was used 
to determine the ratio ofFcERI a expression to expression ofL32+GAPDH for each 
sample. 
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Figure 14. Percent change ofFcERI y mRNA in cells activated by FcERI aggregation or 
ionomycin for 5 hours and compared to unstimulated cells. Phosphorimaging was used 
to determine the ratio ofFcERI a expression to expression ofL32+GAPDH for each 
sample. 
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Figure 15. Percent change of FcERI p mRNA in cells activated by FcERI aggregation or 
ionomycin for 5 hours and compared to unstimulated cells. Phosphorimaging was used 
to determine the ratio of FceRI a expression to expression of L32+GAPDH for each 
sample. 
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FcdU beta chain protein levels are reduced after mast cell activation. 
In order to determine if changes in message levels corresponded to changes in 
protein levels, we assessed protein levels of the different subunits ofFcERI after mast cell 
activation. Fc�::RI alpha protein did not significantly change after mast cell activation 
(Figure 16 and Figure 17). However, there was a slight decrease in protein levels of 
FcERI beta and gamma chains after mast cell 90 minutes and 5 hours of mast cell 
activation. (Figure I 7). 
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Figure 16. FcsRI a protein levels after FcsRI aggregation. BMMC were activated with 
lgE + anti- IgE for 90 minutes, r5 horus and 24 hours, or left unstimulated. Whole cell 
lysates were immunoprecipitated for FcsRI a and immunoblotted for FcsRI a. 
IP: alpha 
WB: alpha 
2 3 4 5 
I. unstimulated cells 
2. lgE + anti-IgE for 90 minutes 
3. lgE + anti-lgE for 5 hours 
4. lgE + anti-IgE for 24 hours 
5. lgG control 
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Figure 17. FcERI y and p protein levels after mast cell activation. BMMC were 
activated with IgE and anti-IgE for 90 minutes, 5 hours and 24 hours, or left 
unstimulated. Whole cell lysates were separated on a 4-20% gradient gel, transferred and 
probed for FcERI p or y. Nitrocellulose was stripped and reprobed for actin. 
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Mast cell activation correlates with downregulation of surface Fc&JU. 
In rodents, the surface expression of FcER1 requires the association of alpha with 
both the beta and gamma chains (Kinet 1999). Thus it is reasonable to presume that 
regulation of the beta subunit could correlate with a change in FcER1 surface expression. 
We activated BMMC for various time points and checked for surface FcER1 by flow 
cytometry using a modified staining protocol. To ensure complete staining of FcER1 on 
the cell surface after activation, we used a three step staining consisting of unlabelled 
lgE, unlabelled anti lgE and FITC coupled anti-IgG. Surface FcER1 is decreased 
approximately 25 percent for the first three days after mast cell activation, compared to 
unstimulated cells and returns to baseline by day 7 (Figure 18). The mechanism by 
which mast cell activation regulates surface expression of FcER1 has not been fully 
elucidated and needs to be further studied. It would be of great interest if a causal 
relationship could be established between mast cell activation, beta chain regulation and 
FcER1 surface expression. 
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Figure 18. Mast cell activation alters surface expression ofFcsRI. BMMC were 
incubated in lgE followed by anti-IgE and cultured for the days indicated. Surface FcsRI 
was measured by flow cytometry. 
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Part II. IL-4 selectively enhances FcyRJII expression. 
Pro-inflammatory signaling followed by a feedback homeostatic effect on the cell 
is a theme constantly explored by our lab. We have previously reported that lnterleukin-
4, which is thought of predominantly as a pro-inflammatory cytokine, downregulated the 
surface expression of Fct::RI and c-kit after 3 days of culture. (Ryan et al. 1998; 
Mirmonsef et al. 1999). In further support of the homeostatic effects of IL-4, we have 
reported that IL-4 in addition with IL-l 0 can induce mast cell apoptosis 6 days after 
culture (Yeatman et al. 2000). This led us to explore the possibility that IL-4 could also 
regulate other surface receptors. 
Mast cells express both the inhibitory and activation low affinity IgG receptors, 
FcyRilb and and FcyRIII, respectively (Daeron 1997). These two receptors have opposite 
functions, FcyRIII aggregation activates the cell whereas FcyRIIb co-aggregation with an 
activating receptor will terminate the activation signal. Despite their opposing functions, 
the receptors have virtually identical extracellular domains and bind lgG complexes with 
the same affinity (Ravetch et al. 2001 ). Recent studies have indicated the importance of 
balancing these receptors in mast cell-mediated inflammation observed in multiple 
sclerosis and rheumatoid arthritis (Lee et al. 2002; Robbie-Ryan et al. 2003). The 
differential regulation of these two receptors was our next area of focus. 
To assess the effects of IL-4 on FcyRIIb and FcyRIII expression, we cultured 
BMMC in IL-3 alone or IL-3 + IL-4. After three days of culture, there was a slight 
increase in Fc;R expression as assessed by flow cytometry with FITC-2.402, an antibody 
that recognizes both FcyRIIb and FcyRIII (Figure 19). To determine if this increase in 
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FcyR expression was due to an increase in FcyRIIb. these BMMC were stained with 
K9.361, an antibody specific for FcyRIIb. No change in FcyRIIb expression was detected 
after the addition of IL-4 in culture for three days as compared to cells cultured in IL-3 
alone (Figure 20). This led us to explore the possibility that IL-4 upregulated FcyRIII 
surface expression without altering FcyRllb expression. In order to test this directly, we 
harvested BMMC from FcRf1. mice that lack FcyRIII but express FcyRIIb, and from 
FcyRJib·f· mice that lack FcyRJib but express FcyRlll (Takai et al. 1994; Takai et al. 
1996). In concordance with K9.361 staining. the addition of IL-4 did not significantly 
alter FcyRJib surface expression. In contrast culture in IL-3+IL-4 consistently increased 
FcyRlll surface expression more than 2-fold over BMMC cultured in IL-3 alone (Figure 
21 ). Because BMMC basal surface levels of FcyRIIb is greater than FcyRIII expression 
(Lobell et al. I 993), an IL-4-mediated increase in FcyRIII could be expected to yield only 
a slight increase in staining total FcyR expression. consistent with the data shown in 
Figure 19. 
IL-4 elevated FcyRJII expression from days 2 through at least day 14 of culture. 
This effect required a minimum of 1 ng/ml of IL-4, with maximal effects at 10 ng/ml. 
FcyRllb expression showed little or no change during this culture period (Figures 22 and 
23). Thus, IL-4 selectively enhanced mast cell FcyRIII surface expression without 
significantly altering the expression ofFcyRIIb for up to 14 days. 
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Figure 19. IL-4 regulates FcyR expression. BMMC derived from wild mice were 
cultured in IL-3 or IL-3 + IL-4 for three days and assessed for FcyR expression by flow 
cytometry with anti-FcyRII!FcyRIII antibody (2.402). Data shown are from at least 7 
independent experiments using 12 different cell populations. (*) = p < 0.05 as 
determined by analysis of variance (ANOV A) and least significant difference (LSD) 
analysis. 
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Figure 20. IL-4 does not regulate the surface expression ofFcyRIIb. BMMC derived 
from wild mice were cultured in IL-3 or IL-3 + IL-4 for three days and assessed for 
FcyRIIb expression by flow cytometry with K9.361. Data shown are from at least 7 
independent experiments using 12 different cell populations. (*) = p < 0.05 as 
determined by analysis of variance (ANOVA) and least significant difference (LSD) 
analysis. 
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Figure 21. FcyR surface staining of FcRy -/-or FcyRIIb -/- mast cells. BMMC derived 
from FcRy -/-or FcyRIIb -/-mice were cultured in IL-3 or IL-3 + IL-4 for three days and 
assessed for FcyR expression by flow cytometry using FITC-2.402. Data shown are 
from at least 7 independent experiments using 12 different cell populations. (* ) = p < 
0.05 as determined by analysis of variance (ANOVA) and least significant difference 
(LSD) analysis. 
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Figure 22. BMMC derived from FcRy +or FcyRIIb + mice were cultured in IL-3 or 
IL-3 + IL-4 and FcyR expression was assessed by flow cytometry on the indicated days 
by FITC-2.4G2 staining. Percent enhancement and standard error measurements were 
calculated by comparing mean fluorescence intensities of IL-3+IL-4 treated BMMC to 
the same cells cultured in IL-3. Data shown are from 9 independent BMMC populations 
analyzed in at least 6 separate experiments. (*) = p < 0.05 as determined by ANOV A and 
LSD analysis. 
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Figure 23. Dose Response to IL-4. BMMC derived from Fc;RIIb +mice were cultured 
in IL-3 or IL-3 with increasing concentrations of IL-4. Percent enhancement was 
calculated by comparing the mean fluorescence of cells cultured in IL-3+1L-4 to cells 
cultured in IL-3. (*) = p < 0.05 as determined by ANOV A and LSD analysis. 
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/L-4 modestly alters FcyRII/a mRNA expression and upregulates protein expression. 
We investigated the mechanism of IL-4-mediated FcyRIII regulation by first 
assessing FcyRIIIa mRNA changes through RNase Protection Assay (RPA) analysis. 
The addition of IL-4 to BMMC cultured in IL-3 for 30 minutes to 72 hours did not 
significantly alter FcyRIIIa mRNA expression, though a moderate increase was noted 
after 96 hours of culture (Figure 24). This finding corroborates a related study in which 
we found that IL-4 downregulates FcERI surface expression without significantly altering 
mRNA expression of FcERI subunits including the FcERiy chain (Gillespie et a!. 2003). 
There are several post-transcriptional mechanisms by which IL-4 could 
increase FcyRIIb surface expression, including increased protein synthesis, increased 
protein stability, and enhanced protein trafficking from preformed intracellular pools. To 
determine if the changes in FcyRIII surface expression were matched by an increase in 
total FcyRIIIa protein levels, we employed 2.402 staining of fixed and permeabilized 
FcyRilb-deficient BMMC. This technique, modeled after intracellular staining of 
cytokines, allowed detection of both surface and intracellular FcyRIIIa, since unlabelled 
2.402 antibody added prior to fixation could block surface but not intracellular FITC-
2.402 staining (data not shown). These experiments demonstrated an IL-4-mediated 
increase in total FcyRIIIa protein expression that resembled the enhanced surface 
expression (Figure 25). 
To determine if the increase m FcyRIIIa protein expression was related to 
changes in protein stability, we employed the translational inhibitor cycloheximide. 
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FcyRlib-deficient BMMC were stimulated for three days with IL-3 alone or with IL-
3+1L-4, after which cycloheximide was added to the cultures. Intracellular 2.4G2 
staining during the proceeding 24 hours showed that the rate of total 
FcyRllia degradation was unaltered by IL-4 treatment, indicating that IL-4 stimulation 
had no effect on FcyRIIIa, stability (Figure 26). 
There remained the possibility that IL-4 facilitated recycling of endocytosed 
FcyRlib, resulting in increased surface expression. Brefeldin A (BFA) prevents surface 
expression of newly synthesized proteins by inhibiting transport from the endoplasmic 
reticulum to the golgi, and blocks surface protein recycling by preventing endosomes 
from fusing with the trans-golgi (Lippincott-Schwartz et al. 1991; Wood et al. 1991). In 
order to determine if IL-4 upregulated FcyRlll surface expression by altering protein 
transport or recycling, we assessed changes in surface levels of FcyRlll after the addition 
of BFA to the culture. FcyRllb-deficient BMMC were cultured in IL-3 alone or IL-3+IL-
4 for 3 days prior to the addition of BFA. Surface FcyRlii expression was measured 20 
hours later, the latest time point possible without affecting cell viability. Cells cultured in 
IL-3+1L-4 had virtually the same sensitivity to BFA as cells cultured in IL-3 alone, as 
both groups demonstrated a 25% reduction in FcyRlii surface expression compared to 
cells treated with vehicle alone (Figure 27). 
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Figure 24. IL-4 has minimal effects on transcription. Wild type BMMC were stimulated 
for 4 days with the indicated cytokines, and total RNA was subjected to RPA analysis as 
described in Materials and Methods. Data shown are a representative BMMC population 
from 3-11 populations assessed in 5 independent experiments spanning days 1-4. (B) 
Summary of percent change in FcyRllla mRNA in cells cultured in IL-3+IL-4, as 
compared to cells cultured in IL-3 alone. Phosphorimaging was used to determine the 
ratio ofFcyRll a expression to expression ofL32+GAPDH for each sample. This ratio 
was used to compare FcyRllla expression in BMMC treated with IL-3+1L-4 to those 
cultured in IL-3 alone. Data are means and standard errors from 3-11 samples from 5 
independent experiments. 
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Figure 25. Intracellular staining of FcyRllla. BMMC derived from FcyRllba -/- mice 
were cultured in the indicated cytokines for three days, and assessed for total 
FcyRllla expression by intracellular staining with FITC-2.402, as described in Materials 
and Methods. Statistical significance was evaluated as described in figure 1. (*) = p < 
0.05 as determined by ANOV A and LSD analysis. 
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Figure 26. IL-4 enhances FcyRIII expression without altering protein stability. BMMC 
derived from FcyRIIba -!-mice were cultured for three days in IL-3 alone or in IL-3+IL-
4 prior to the addition of cycloheximide ( 4!-!g/ml final) for the times indicated. 
Intracellular staining with 2.4G2 was used to assess total FcyRIIIa expression. Percent 
change in expression was determined by comparing mean fluorescence intensities of cells 
treated with cycloheximide to those in DMSO. Data shown are means and standard 
errors of9 different BMMC populations from three representative experiments. 
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Figure 27. IL-4 does not affect FcyRIII recycling. BMMC derived from FcyRilba 
+mice were cultured for three days in IL-3 alone or in IL-3+1L-4 prior to the addition of 
Brefeldin A (3ug/rn1) for 20 hours. Staining with 2.4G2 was used to assess surface 
FcyRIII expression by flow cytometry. Percent inhibition was determined by comparing 
mean fluorescence intensities of cells treated with BFA to those treated with media alone. 
Data shown are means and standard errors of 6 different cell populations in three 
independent experiments. 
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The role of Stat6 in /L-4-mediated Fey Rill expression. 
Because of the importance of Stat6 in IL-4 signaling, we explored its role in IL-4 
mediated FcyRJII upregulation. In order to determine if Stat6 was sufficient to 
upregulate FcyRIII, we infected FcyRJlb deficient BMMC with a bicistronic retroviral 
expression vector encoding green fluoresence protein (GFP) alone or GFP and a 
constitutively active mutant of Stat6, termed Stat6VT (Daniel et al. 2000; Zhu et al. 
2001). These cells were maintained in IL-3 alone and assessed for FcyRJII expression 5 
days post-infection. As shown in Figure 28, Stat6VT increased FcyRJII approximately 
surface expression 2-fold, closely matching IL-4-mediated upregulation (Figure 21 ). 
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Figure 28. Stat6 activation is sufficient to enhance derived from FcyRlll expression. (A) 
BMMC derived from FcyRIIb _,_ mice were transfected with bi-cistronic retrovirus 
expressing GFP alone (lower left), or GFP and constituitively active Stat6VT (lower 
right) as described in Materials and Methods. The cells were cultured in IL-3 for three to 
five days and stained with PE-2.4G2 to determine surface FcyRIIIA expression. The 
upper dot plot is a negative control stained with unlabelled 2.4G2 before the addition of 
PE-2.4G2. (B). Average mean fluorescence intensity and standard errors of 6 samples. 
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IL-4 increases FcyR-mediated inflammatory function on wild type mast cells. 
We assessed the effects of IL-4 stimulation on the immediate phase of mast cell 
activation by measuring FcyR-induced release of �-hexosaminidase, a marker of mast 
cell degranulation (Schwartz et a!. 1979). Wild type BMMC expressing both FcyRIIb 
and FcyRIII were cultured in IL-3 alone or in IL-3+1L-4 for three days, followed by 
crosslinkage with anti-FcyRIIb/FcyRIII mAb (2.4G2) and goat anti-rat IgG for 60 
minutes. Release of the granule component �-hexosaminidase into culture supernatants 
was then assessed by enzyme assay. Degranulation was measured as percent specific 
release of stimulated cells over unstimulated cells. BMMC cultured in IL-3 alone 
showed no significant �-hexosaminidase release after 2.4G2 rosslinkage, consistent with 
the high level of FcyRIIb expression on these cells (Lobell et a!. 1993). However, 
BMMC cultured in IL-3+1L-4 demonstrated enhanced P-hexosaminidase release after 
activation (Figure 29). 
While mast cell degranulation is part of the early phase of mast cell activation, 
cytokine production is an indicator of the late phase response, and is a critical component 
of inflammatory infiltration and tissue damage (Wills-Karp 1999). To determine if IL-4 
altered FcyR-mediated cytokine production, wild type BMMC were cultured for three 
days in IL-3 alone or IL-3 +IL-4, followed by activation with FcyR crosslinkage. TNFa 
mRNA and protein levels were measured by RPA and ELISA, respectively. These 
experiments showed that IL-4 enhanced both FcyR-mediated TNFa mRNA levels and 
protein secretion (Figure 30 and Figure 31 ), though this increase was modest in 
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companson to the effects on beta hexosaminidase release. Together with the 
degranulation studies, these results demonstrate that IL-4 stimulation enhances the early 
and late phases ofFcyR-mediated pro-inflammatory mediator secretion in mast cells. 
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Figure 29. IL-4 enhances FcyR-mediated P-hexosaminidase release on wild type 
BMMC. Wild type BMMC were cultured in IL-3 alone or in IL-3 plus IL-4 for the 
number of days indicated. Cells were then stimulated with 2.402 and goat anti-rat lgG 
(FcyR XL) or were left unstimulated, and assessed for P-hexosaminidase release as 
described in Materials and Methods. Percent specific release was calculated by 
subtracting P-hexosaminidase release in non-activated cells from that of FcyR XL­
stimulated cells as described in Materials and Methods. Data shown are means and 
standard errors from a minimum of 6 BMMC populations assessed in a minimum of 5 
independent experiments. (*) = p < 0.05 when comparing to IL-3 alone, as determined 
by ANOV A followed by LSD analysis. 
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Figure 30. IL-4 alters FcyR-mediated cytokine mRNA synthesis. Wild type BMMC 
were cultured for 3 days with the IL-3 or IL-3+1L-4, followed by FcyR XL as described 
previously. Total RNA was subjected to RPA analysis. Data shown are one 
representative RP A from 5 independent experiments with similar results using 3-11 
independent BMMC populations. (B) Summary of changes in TNFa mRNA expression. 
Pixel intensities from (A) were obtained by phosphorimager analysis, and the ratio of 
cytokine gene expression to the sum of the L32 and GAPDH housekeeping gene 
expression was determined. Data are means and standard errors from 3-11 samples from 
3-5 independent experiments. 
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Figure 31. IL-4 effects on TNF alpha release. Wild type BMMC were cultured in the 
indicated cytokines for 3 days, then stimulated with FcyR XL for 24 hours. TNFa release 
was measured using ELISA as described in Materials and Methods. Data shown are 
means and standard errors from 3 different BMMC populations assessed in 3 independent 
experiments. Each sample was done in triplicate. The lower limit of detection was 15.4 
pg/ml. for TNFa. (*) = p < 0.05 when compared to cells cultured in IL-3 alone, using 
ANOV A and LSD analysis. 
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DISCUSSION 
FccRI aggregation initiates a signaling cascade that results in degranulation, the 
immediate production of lipid-derived mediators, and the later release of newly 
transcribed chemokines and cytokines. With the advanced technology of eDNA and 
oligonucleotide arrays, it is now possible to monitor the genome wide transcriptional 
profile of cells and tissues (Brown et a!. 1999). The MG-U74 GeneChip contains the 
probe set for over 6000 full length genes and 6000 expressed sequence tags (Af:fYmetrix). 
Using these probe arrays we were able to assess the global transcriptional changes that 
occurred after mast cell activation for 90 minutes, 5 hours and 24 hours, and compare 
these results to cells that remained unstimulated. These time points correspond to the 
early, late and resolution phases of mast cell activation. Analysis with Microarray Suite 
5.0 (Affymetrix) revealed that 937 of these probes were regulated by FccRI crosslinkage 
in at least one time point, and that approximately half of these probes were for ESTs 
(Figure 1 ). Further analysis revealed that 259 probes for full length genes were regulated 
at least two fold by FccRI crosslinkage (Appendix 1). 
Gene changes over time revealed that the transcriptional profiles were similar at 
90 minutes, 5 hours and 24 hours after activation. The most regulated category at each 
time point was DNA binding genes, mostly those involved in transcriptional regulation 
and cell cycling. There were however general differences. Ninety minutes after 
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activation, the three most abundantly transcribed genes compared to unstimulated cells 
were the chemokines CCL7 (MCP-3), CCL4 (MIP1�) and CCL-3 (MIP1u) which were 
upregulated an astonishing 502, 179 and 168 fold, respectively (Table 1 ). In comparison, 
the most abundantly transcribed genes after 5 hours were CCL-3 (MIP1a), CCL7 (MCP-
3), and secreted phosphoprotein 1 (osteopontin), which increased a modest 59, 55, and 30 
fold respectively. Twenty-four hours after activation, the most abundantly transcribed 
gene, endostatin, is induced only 10.55 fold over unstimulated cells (Table 3). Looking 
at the total number of genes that were regulated, there were a total of 174 genes that were 
regulated at least two fold after ninety minutes, 202 after 5 hours, and a meager 69 genes 
were regulated after 24 hours. Upon analysis with DAVID, which integrates information 
from a variety of sources including the National Library of Medicine and the Gene 
Ontology consortium, of the 20 most changed transcripts at 24 hours after activation, 12 
of them remained unclassified according to GO analysis (Glynn Dennis Jr.). It can be 
reasonably inferred that most of these gene changes are secondary to Fc�:RI aggregation, 
and are most likely due to an autocrine effect from the mast cell release of preformed 
mediators and/or cytokines. Therefore it is difficult to interpret these results without 
knowing the microenvironment of the mast cell at the time. 
Our analysis revealed genes previously unreported to be regulated in mast cells. 
Some of these will be discussed in detail. 
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Osteopontin. This gene is also known as secreted phosphoprotein 1, and early T 
lymphocyte activation 1 (ET A-1 ). Osteopontin is expressed by T cells and is a regulator 
of T helper 1 immunity (Patarca et al. 1989). It was previously reported that ET A-1 
sustained the autoimmune responses associated with EAE, the murine model of multiple 
sclerosis. Mice deficient in ETA-1 had lower clinical scores, faster recovery, and fewer 
spontaneous relapses as well as decreased inflammatory infiltration and demyelination of 
the spinal cord. T cells from these mice also produced less TNFu and IFNy. (Jansson et 
al. 2002). Mast cells have recently been reported to play an essential role in the 
pathology of EAE. Mice deficient in mast cells had significantly reduced disease 
incidence as well as decreased clinical scores compared to wild type littermates, and 
reconstitution with mast cells restored disease symptoms (Secor et al. 2000). It has also 
been reported that the expression of Fe receptors is critical in the regulation of this 
disease, but the link between mast cell activation and disease pathology remains to be 
elucidated (Brown et al. 2002; Robbie-Ryan et al. 2002; Robbie-Ryan et al. 2003). 
We found that osteopontin is the third most upregulated gene five hours after mast cell 
activation, just after CCL3 and CCL 7 (Table 2). If it was shown that mast cells produce 
osteopontin after activation, it would be an interesting functional link between mast cells 
and EAE worthy of further exploration. 
Osteopontin is also known to be important in cell attachment and motility, by 
engaging the surface antigen CD44. Interaction between osteopontin and CD44 can 
regulate macrophage migration (Weber et al. 1996; Weber et al. 2002). If mast cells 
are able to make osteopontin, it is possible that they can recruit other inflammatory cells 
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such as macrophages via their CD44 expression. This could be an important component 
in mast cell involvement in T helper 1 immune responses and diseases. 
CD44. In addition to binding osteopontin, CD44 is the major cell surface receptor 
for the nonsulfated glycosaminoglycan hyaluronan (HA). CD44 is a transmembrane 
adhesion receptor that can be expressed as a standard protein or as a variant containing 
spliced exon sequences. Although these different variants have been demonstrated to 
have slightly different functions, CD44 generally is important in cell migration, including 
lymphocyte trafficking, limb development, axon growth, wound healing, tumorigenesis, 
metastasis formation, and autoimmune diseases. Anti-CD44 treatment has demonstrated 
its role in collagen induced arthritis, experimentally induced colitis and delayed type 
hypersensitivity reactions (Mikecz et al. 1995; Ponta et al. 1998; Nedvetzki et al. 
1999). One recent study reported that administration of anti-CD44 monoclonal 
antibodies prevented lymphocyte and eosinophil accumulation in the lung after challenge 
with helminth and mite antigens. Treatment with this antibody blocked the elevation ofT 
helper 2 cytokines, chemokines, and leukotrienes in bronchoalveolar lavage fluid, as well 
as airway hyperresponsiveness (Katoh et al. 2003). Thus CD44 could be important in 
airway allergic inflammation. Previous studies have reported the expression of CD44 on 
human mast cells (Nedvetzki et al. 1999). Our GeneChip analysis identified CD44 as the 
ninth most increased transcript five hours post mast cell activation (Table 2). 
Considering the importance of mast cells in allergic lung inflammation, the regulation of 
CD44 surface expression after mast cell activation could be important in the pathology of 
121 
this disease. CD44, as well as HA ligand has also been found in considerable amounts in 
the joint synoviurn of rheumatoid arthritis patients. In addition, anti-CD44 monoclonal 
antibody can markedly reduce inflammation in murine models of RA (Naor et al. 2003). 
It is possible that mast cell expression of CD44 regulates its role in these conditions and 
would be interesting to pursue further. 
Protease-activated G protein-coupled receptor. Par1, also known as F2R or 
coagulation factor ll (thrombin) receptor, is a G protein-coupled receptor that mediates 
cellular responses to thrombin. Thrombin is a serine protease usually generated in 
response to tissue damage or inflammation, and acts to form fibrin matrices and activate 
platelets and endothelial cells during injury (Kannan 2002). It has been reported that 
mast cells express Par1 and signaling could induce adherence to fibronectin. We report 
that mast cell activation induces the transcription of Par1 around 3-5 fold during the 90 
minutes through 24 hour time points measured (Figure 9, Table 7). Therefore, FcDRl 
aggregation could upregulate the surface expression of Par 1, allowing for further 
activation of mast cells near tissue injured sites where thrombin is prevalent, resulting in 
further mast cell activation by other receptors. 
Nuclear receptor subfamily 4, group A, member (Nurr77). Nurr77, also known 
as TR3 or NGFI-B, is an immediate early response gene that is rapidly induced during 
apoptosis of immature thymocytes, T cell hybridomas and other various cancer cells. 
Inhibition of Nurr77 activity inhibits apoptosis in T cells and its overexpression leads to 
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massive apoptosis. This protein has also been shown to play a role in TCR mediated cell 
death, thymocyte negative selection, as well as caspase independent activation induced 
cell death in macrophages (He 2002; Kim et al. 2003). Nurr77 is a steroid receptor and a 
member of the orphan nuclear receptor family, because its ligand is unknown. We found 
that Nurr77 gene expression peaked at ninety minutes post FcsRI aggregation, increasing 
38 fold over unstimulated cells, and levels returned to baseline by 5 hours (Figure 6, 
Table 4). Nurr77 expression in mast cells has not been reported. The early upregulation 
of this gene could be indicative of an apoptotic phenotype induced by FccRI aggregation. 
Schlafen 2. Schlafen 2 belongs to a family of genes identified because of their 
upregulation during positive selection ofT lymphocytes. Schlafen is German for "sleep", 
because induction of this gene causes cell cycle arrest (Schwarz et al. 1998). We found 
that schlafen2 expression was downregulated between 3-6 fold ninety minutes after mast 
cell activation, and that transcript levels return to baseline by 24 hours. (Figure 7, Table 
5). To our knowledge, there are no reports of schlafen2 expression in mast cells. 
However, if it could be demonstrated that schlafen2 protein is expressed and regulated in 
mast cells by activation, it would be interesting if this affects cell survival after 
stimulation. 
Nuclear factor, interleukin 3 regulated (NFIL3 aka E4BP4). E4BP4 was 
originally identified by its ability to recognize and repress the adenovirus E4 promoter, 
hence its name adenovirus E4 promoter-binding protein. Identified as NF-IL3A in T 
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cells, E4BP4 is a basic region/leucine zipper transcription factor known to be upregulated 
by IL-3 and capable of binding the human IL-3 promoter (Cowell 2002). E4BP4 
expression was induced in a pro-B cell line Ba/F3 after stimulation with IL-3, and forced 
expression delayed apoptosis caused by IL-3 deprivation, while over expression of a 
dominant negative E4BP4 attenuated the survival response ofiL-3 (Ikushima et a!. 1997). 
We found by microarray analysis that FccRI aggregation regulated the expression of this 
transcript at all three time points assessed. Transcript levels are increased both 90 
minutes and 5 hours after mast cell activation (7 fold and 3 fold respectively), but by 24 
hours, E4BP4 is the second most downregulated gene, 4 fold below unstimulated cells 
(Figure 6, Table 3, Table 4). It can be inferred that initially mast cell activation enhances 
mast cell survival, but due to an unknown regulatory mechanism, E4BP4 expression is 
repressed by 24 hours. This implies a greater sensitivity to apoptotic signals during the 
resolution phase of mast cell activation. 
N-myc downstream regulated 1 (NDRGJ). NDRGI is a serine protease that is strongly 
induced in several cell types during cellular differentiation or stress. 1n most reports, the 
expression of this gene has been found to be growth inhibitory, but when transfected into 
RBL cells, proliferation remained unchanged but degranulation after FccRI aggregation 
was enhanced (Kurdistani et a!. 1998; Guan et a!. 2000). Recently, a study found that 
mast cells co-cultured with fibroblasts in the presence of stem cell factor had high levels 
of NDRG 1, and that the levels correlated with enhanced degranulation (Taketomi et al. 
2003). Our microarray analysis revealed that 90 minutes after mast cell activation, this 
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gene is upregulated almost 13 fold and back to baseline 24 hours later. It is possible that 
upregulation of this gene could allow for the mast cell to mature after activation, thus 
enhancing its response to other stimuli. 
Microarray analysis reveals genome wide gene expression patterns after mast cell 
activation, therefore rather than looking at one gene and its effect on a biological process, 
it is possible to look at temporal expression patterns of many related genes and predict a 
potential concerted effect on biological function. To illustrate this point, the regulation of 
mast cell survival cell after FcERl activation was analyzed. Genes known to be involved 
in cell cycle regulation were analyzed, and their expression patterns in context of other 
gene changes were summarized in a table (Table 32). Collectively, the gene expression 
profiles are inconclusive. Ninety minutes after mast cell activation, Nurr77, a pro 
apoptotic gene is highly upregulated, and p21 is also elevated compared to unstimulated 
cells. However, schlafen2 which induces cell cycle arrest, is downregulated at this time 
point, and E4BP4 is upregulated, arguing for cell cycle progression and survival. 
The literature on FcERl aggregation and mast cell survival are mixed as well. 
Some studies argued that FcERl aggregation enhanced survival and proliferation, 
prevented apoptosis due to factor withdrawal (Plaut et a!. 1989; Matsuda et a!. 1999). 
One study using BMMCs found that FcERl aggregation enhanced survival through the 
upregulation of AI, a member of the Bcl-2-family (Xiang et a!. 2001). Others indicated 
the opposite, stating that FcERl aggregation significantly reduced proliferation in 
response to growth factors (Tsai et a!. 1993). The difficulty interpreting the literature lies 
in the fact that all of the studies use different cell types and culture conditions (Kawakami 
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et al. 2002). Further studies are needed to determine if these genes are even expressed 
as proteins, and if they play a significant role in mast cell survival and proliferation. 
Table 8. Summary of Genes involved in cell cycle regulation, apoptosis and 
survival. 
Gene Role 90 minutes 5 hours 24 hours 
Cyclin 02 cell cycle progression t 
Cyclin 03 cell cycle progression -!-
Cyclin B2 cell cycle progression -!- -!-
p19 cell cycle arrest -!--!- -!-
p21 cell cycle arrest t 
schlafen2 cell cycle arrest -!--!-
Rb cell cycle arrest -!-
Nurr77 apoptosis ttt 
E4BP4 anti apoptotic t t -!-
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Regulation of the beta subunit by Fct:Rl aggregation. 
Microarray analysis revealed that FcERl aggregation resulted in a four fold 
decrease in beta chain mRNA after five hours, without significantly altering alpha or 
gamma transcripts (Figure 9, Table 7). RPA analysis partially confirmed the array, 
demonstrating that 5 hours after activation, the message levels of the alpha chain remain 
unchanged, whereas beta chain levels decrease significantly (Figure 12, Figure 13, Figure 
15). RP A analysis of the gamma subunits however gave mixed results and further studies 
are needed to clarify if gamma is regulated by FcERl aggregation (Figure 12, Figure 14). 
Little is known about the transcriptional regulation of the individual subunits of 
FcERl. Previous studies have demonstrated that IL-4 can upregulate the transcription of 
FcERla in human mast cells, and that IFNy can increase the rate of FcRy chain 
transcription (Brini et a!. 1993; Toru et a!. 1996; Xia et a!. 1997). However, there 
is to our knowledge no literature on known factors that specifically regulate transcription 
of the beta subunit. Recently, Maeda et. a!. published that GATA-1 can bind the beta 
subunit promoter at four different sites, and that these four sites are required for full 
transcriptional activation by GATA-1 (Maeda et a!. 2003). GAT A-1 is highly expressed 
in mast cells and could be the primary transcription factor responsible for its expression 
(Weiss et a!. 1995). Our microarray analysis revealed that GATA-1 transcript levels 
were slightly downregulated after mast cell activation (Appendix 1 ). It is possible that 
this moderate decrease in GATA-1 transcript results in less total GATA-1 protein, 
leading to decreased transcription of the beta subunit. It is also plausible that FcERl 
aggregation regulates the expression of other transcripts that have an effect on the 
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stability of GAT A-1 transcript and/or protein, or affect the ability of GAT A-1 to bind the 
promoter of the beta subunit. It is also possible that a different yet unidentified 
transcription factor is involved in beta chain regulation. 
FcERl could also regulate beta transcript by decreasing its stability or increasing 
degradation. Ribonuclease Protection Assay (RP A) can only assess steady state levels of 
mRNA. Repeating the experiments using Actinomycin D, a transcriptional inhibitor, 
could give insight into FcERl activation and beta chain regulation. If the half-life of the 
P subunit mRNA is decreased by FcERl crosslinkage, this could provide evidence that 
FcERl activation is either actively mediating an increase in the degradation of mRNA or 
is alleviating some protection from degradation. Further studies are needed to elucidate 
the potentially complex steps that connect FcERl aggregation with transcriptional control 
of the beta subunit. 
We found that downregulation of the beta transcript correlated with 
downregulation of the beta protein, with no change in alpha protein levels (Figure 16 and 
Figure 17). Again, gamma protein levels seemed reduced 90 minutes after activation but 
this needs to be repeated in order to confirm. Western blotting can only indicate steady 
state levels of protein, thus studies utilizing treatment with the translational inhibitor 
cycloheximide can determine the effects of FcERl aggregation on protein stability. 
Finally, we found that FcERl aggregation correlated with a decreased surface 
expression of FcERl (Figure 18). This corroborates the reduced expression of FceRI p, 
which is required for FcERI surface expression. Further studies are needed to directly 
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connect mast cell activation to beta chain regulation and regulation of the surface 
expression of Fc�::RI. 
A potential factor that could regulate the surface expression of Fc�::RI is through 
the mechanism of a newly described isoform of the beta subunit , �T· It has recently been 
discovered that alternative splicing of the beta subunit gene results in the expression of a 
truncated variant, �T, that can compete functionally with its normal counterpart. This 
isoform pairs with immature Fc�::Ria and inhibits its maturation , thus preventing surface 
expression of Fc�::RI. �and �Tare expressed in mast cells so the balance between the two 
isoforms could alter the mast cell response. The mechanism that controls the splicing of 
the beta chain is still unknown (Donnadieu et al. 2003). It is possible that mast cell 
activation initiates a signal cascade resulting in the upregulation of the �T while 
downregulating or even maintaining � levels. The probe used for the Ribonuclease 
Protection Assay binds both isoforms of the beta gene. Therefore we could not determine 
if the downregulation of beta message seen 5 hours after activation is due to decreased �, 
�T or both. �T is a slightly smaller protein than B, but due to its low level of expression 
and instability, it is difficult to detect without proteasome inhibitors. We would need to 
repeat our studies using a probe that could bind only �T or �, and repeat the western blots 
using protease inhibitors. 
Another experiment that would more directly link beta chain downregulation with 
inhibition of Fc�::RI surface expression is needed. We propose the transfection of BMMC 
with a vector containing the beta subunit with a constituitively active promoter. These 
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cells could be activated with IgE+anti-IgE, and surface expression could be analyzed by 
flow cytometry. If the Fc�::Rl expression remains stable, this could indicate that 
downregulation of the beta gene is required for downregulation of surface Fc�::Rl. 
If decreased beta chain resulted in downregulation of Fc�::Rl surface expression, 
this could lead to decreased activation of the mast cell. Human mast cells do not require 
the beta subunit for Fc�::Rl expression, however the trimer does not signal nearly as well 
as its tetrameric counterpart. Increased expression of this form after mast cell activation 
could be homeostatic, preventing further activation to dampen the inflammatory 
response. 
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Part II. Interleukin-4 regulation of Fey Rill expression and signaling. 
BMMC cultured in the presence of IL-4 for three days had a twofold increase in 
surface FcyRIII, with no significant change in surface levels of FcyRIIb. This 
upregulation of surface FcyRIII could be seen through day 14 of culture with as little as I 
ng/ml of IL-4. In an attempt to determine the level of regulation by IL-4, we looked at 
total mRNA and intracellular protein levels of Fcyllla. We found that total intracellular 
levels of FcyRllla were elevated by the second day of culture, mimicking the surface 
expression of FcyRIII. However, there was only a nominal increase in mRNA levels. 
Thus it did not appear that the upregulation of surface FcyRIII was a result of IL-4 
enhanced transcription of FcyRIIIa. 
To assess the possibility that IL-4 regulation occurs post transcriptionally, we 
employed the translational inhibitor cycloheximide to determine if IL-4 was enhancing 
FcyRllla protein stability. After 3 days of culture in either IL-3 alone or IL-3 + IL-4, 
cycloheximide was added to the cell culture. We found that cells cultured in the presence 
of IL-4 had the same rate of degradation of FcyRIIIa as cells cultured in IL-3 alone, 
indicating that IL-4 did not affect protein stability (Figure 26). 
There remained the possibility that IL-4 facilitated recycling of endocytosed 
Fey Rill, resulting in increased surface expression. Brefeldin A (BFA) prevents surface 
expression of newly synthesized proteins by inhibiting transport from the endoplasmic 
reticulum to the golgi, and blocks surface protein recycling by preventing endosomes 
from fusing with the trans-golgi (Lippincott-Schwartz et al. 1991; Wood et al. 1991) 
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Cells cultured in IL-3+1L-4 had virtually the same sensitivity to BFA as cells cultured in 
IL-3 alone (Figure 27). These data agree with an earlier study by Kubo and co-workers 
showing that surface FcyRIII is very stable and undergoes little receptor recycling (Kubo 
et a!. 2001). Collectively these data argue that IL-4 enhances FcyRIIIa protein 
expression by increasing protein synthesis, without altering FcyRIIIa mRNA levels, 
protein stability or surface protein recycling. One possible mechanism by which this 
could occur is through enhancing translational efficiency. IL-4 signaling may regulate 
mRNA binding proteins, leading to increased translation without altering mRNA levels 
(Al-Maghrebi et a!. 2002). 
The ability of IL-4 to enhance FcyRIII expression is an interesting contrast to our 
previous finding of IL-4-mediated downregulation of FcERI. Although these events may 
have opposing effects on mast cell function, reduced FcERI expression may be related to 
the increase in FcyRIII. Our recent study demonstrated that IL-4 diminishes FcERI 
expression by decreasing FcERI� protein expression without affecting FcERia or FcRy 
(Gillespie et a!. 2003). Since FcyRIII expression requires pairing with FcERiy but not 
FcERI�, it is possible that loss of FcERI� results in a de facto increase in FcyRIII 
expression due to reduced competition for the obligatory gamma chain. This theory is 
supported by the demonstration that FcERia-deficient mast cells exhibit increased 
FcyRIII expression (Dombrowicz et a!. 1998). Further, these changes would likely be 
mast cell-specific, explaining the differences between our study and those of Te V elde et 
a!., and Pricop et a!. (te Velde et a!. 1990; Pricop et a!. 2001) who found that IL-4 inhibits 
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FcyRIII expression on monocytes. Therefore IL-4 may be enhancing surface FcyRIII 
expression both by increasing FcyRIIla protein synthesis and limiting competition for its 
expression partner, FcERiy. 
Because of the importance of Stat6 in IL-4 signaling, we explored the role of 
Stat6 in IL-4 mediated Fc}Rlll upregulation. We found that Stat6 activation alone is 
sufficient to increase FcyRIII expression, data in keeping with IL-4 mediated regulation 
of FcERI (Ryan et a!. 1998; Gillespie et a!. 2003). Since FcyRIII expression is enhanced 
without altering FcyRilla transcription, it would appear that Stat6-mediated effects are 
indirect, perhaps by regulating expression of RNA binding proteins as previously 
suggested. 
Increasing expression of pro-inflammatory FcyRIII might enhance mast cell 
responses to lgG-mediated stimuli, however co-expression of inhibitory FcyRilb 
receptors could block these signals, preventing mast cell activation. With recent data 
emphasizing the role of mast cell FcyRIII-mediated signaling in inflammatory disease 
(Oettgen et a!. 1994; Takai et a!. 1994; Hazenbos et a!. 1996; Dombrowicz et a!. 1997; 
Miyajima et a!. 1997), the effect of IL-4 on lgG-mediated activation of wild type mast 
cells has clinical importance. BMMC cultured in IL-3 alone showed no significant 
�-hexosaminidase release after FcyR crosslinkage, consistent with the high level of 
FcyRIIb expression on these cells (Lobell et a!. 1993). However, BMMC cultured in IL-
3+IL-4 demonstrated enhanced �-hexosaminidase release after activation (Figure 6). 
These data indicate that selective upregulation of FcyRIII by IL-4 is functionally 
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significant, leading to increased lgG-mediated mast cell degranulation. BMMC cultured 
in IL-4 also had enhanced FcyR-mediated TNFa mRNA levels and protein secretion, 
although this increase was modest in comparison to the effects on beta hexosaminidase 
release. Together with the degranulation studies, these results demonstrate that IL-4 
stimulation enhances the early and late phases of FcyR-mediated pro-inflammatory 
mediator secretion in mast cells. 
The ability of IL-4 to alter FcyR signaling in the context of both pro- and anti­
inflammatory IgG receptors could be due solely to the selective upregulation of FcyRIII. 
However, FcyRIIb expression is still considerable after IL-4 stimulation. It remains 
possible that enhanced FcyR-rnediated mast cell activation is due partly to enhanced 
FcyRIII expression and partly to inhibition of FcyRIIb signaling. 
FcyRIIb mediated inhibitory signaling requires an intracellular immunoreceptor 
tyrosine-based inhibitory motif (ITIM) that preferentially interacts with Src homology 2-
containing-inositol 5'-phosphatase, or SHIP-I. Upon FcyRIIb aggregation with an 
activation receptor such as the BCR, TCR., Fcf:RI or FcyRIII, lyn phosphorylates the 
critical tyrosine within the ITIM motif, recruiting SHIP-I by its SH2 domain. This 
recruitment results in tyrosine phosphorylation of SHIP-I. SHIP-I subsequently 
dephosphorylates the major PBK product, PIP3, which abolishes the recruitment of PH 
domain containing molecules, abrogating activation receptors signaling (Rauh et al. 
2003). Normally, mast cells express more FcyRilb than FcyRIII and so the activation 
signal is abrogated, preventing degranulation (Lobell et al. 1993). However, it is possible 
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that in the presence of IL-4, this inhibition is relieved. This could occur through 
inhibition of the phosphorylation of ITIM or decreased recruitment or activation of 
SHIP. Either scenario could reduce FcyRIIb signaling, allowing FcyRIII to activate the 
cell. Thus the effects ofiL-4 on SHIP-1 expression and activation warrant further study. 
The current study demonstrates that IL-4 upregulates FcyRIII surface expression 
without significantly altering expression of FcyRIIb. IL-4 conveys these changes via 
alterations in FcyRIIIa protein expression without affecting mRNA synthesis, protein 
stability, or receptor recycling. Stat6 activation alone induces FcyRIII upregulation, 
emphasizing the importance of this transcription factor in IL-4-initiated signal 
transduction. Importantly, modifying the surface ratio of FcyRllb to FcyRIII is 
functionally significant, allowing for degranulation and cytokine production after FcyR 
crosslinkage. Understanding FcyR regulation could be significant to inflammatory 
disease, as recently demonstrated in a rodent model of multiple sclerosis, where selective 
FcyRIII expression on mast cells altered disease severity (Robbie-Ryan et a!. 2003). 
Similarly, there is recent evidence that FcyR play an important role in a mouse model of 
rheumatoid arthritis (Lee et a!. 2002). Manipulation of the FcyRllb/FcyRIII ratio by 
cytokines could therefore be important for controlling and treating inflammatory disease. 
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Probe 10 Gene Name Gene Symbol Average Fold Change 
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96713_at 3'-phosphoadenosine 5'-phosphosutfate synthase 2 Papss2 -1.41 -4.00 -1.14 
96989_at ?-dehydrocholesterol reductase Ohcr7 -1.63 -2.96 1.05 
103024_at a disintegrin CW'ld metalloprotease domain 8 AdamS 3.09 3.25 1.68 
92581_at acetyl-Coenzyme A dehydrogenase, medium chain Acadm -1.65 -0.13 1.22 
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104156_r_at activating trW�scription factor 3 Alf3 39.09 0.54 0.34 
104155_f_at activating transcription factor 3 Alf3 46.15 1.51 -1.30 
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103392_at adenytate cyclase 7 Adcy7 -1.10 2.18 2.21 
95148_at adenylate kinase 2 Ak2 -0.02 2.24 -1.47 
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160082_s_at ADP-ribosylation factor 4 Arl4 1.54 0.12 -1.09 
100903_at ADP-ribosyltransferase (NAD•; poly(ADP-ribose) polymerase)-tike 2 Adprtl2 -2.51 -1.58 -1.22 
102249_at advillin A vii 1.25 2.02 1.29 
93904_f_at AF059706:clone N 1.1.b immunoglobulin heavy chain VDJ region gene -2.38 -19.10 -2.20 
99993_at alcrtyl (membra'le) aminopeptidase An pep -1.22 1.44 1.78 
160215_at anino-terminal enhancer a split Aes 0.00 -1.34 1.13 
102710_at a-nyioid beta (A4) precursor protein-binding, family B. member 1 interactin! Apbb1ip -2.83 1.52 -1.17 
93496_s_at amyloid beta (A4) precursor-like protein 2 Aplp2 1.75 1.93 -0.04 
102815_at am6:10nA11 Anxa11 -1.06 1.41 1.36 
93083_at annexin AS Anxa5 1.50 1.96 1.43 
99457_at a1tigen identified by moooctonal antibody Kl 67 Mki67 -2.04 -12.57 -3.11 
103796_at apoptotic protease activating factOf 1 Apaf1 -1.97 -1.09 1 . 06 
102200_at aquaporin 8 Aqp8 1.75 4.30 0.42 
95600_at ariadne homolog 2 (D rosophila) Arih2 8.02 3.35 1.97 
160495_at �hydroccwbon receptor Ahr 1.50 1.82 1.62 
93984_at ATPase inhibitor Alpi -1.42 -1.45 0.00 
103275_at ATPase, H+ transporting, lysosoma VO subunit a isoform 1 Alp6v0a1 0.46 2.98 1.54 
99579_at ATPase, N a+IK+ transporting, beta 3 polypeptide Atp1b3 -1.20 -1 .27 1.05 
93414_at ATP-binding cassette, sub-family B (MDRfTAP), member 18 Abcb1b -3.97 -5.49 1.08 
160612_at ATP-binding cassette, sub-family G (WHITE). member 1 Abcg1 -2.00 O.o7 1.82 
101521_at bacukwiraiiAP repeat-containing 5 BireS -1.50 -3.85 -2.54 
93527_at basic tra1scription element binding protein 1 Bleb1 8.91 3.36 0.06 
98868_at B-eall leukemia/lymphoma 2 Bcl2 1.85 -1.88 -0.11 
93104_at B-cell translocation gene 1, anti-proliferative Btg1 4.53 2.89 1.90 
96148_at 8-cell tra"LSiocation gene 3 Btg3 4.89 2.32 0.17 
96255_at BCL2/adenovirus E1B 191-;0a-interacting protein 3-like Bnip31 0.20 -<3.40 0.17 
93088_at bet.a-2 microglobulin B2m 0.03 1.13 1.40 
98433_at BH3 interacting domain death agonist Bid -2.84 -1.75 1.22 
98052_at bkx:ked ea1y in tra1sport 1 homolog (S. cerevisiae)-like Bel11 0.48 2.16 1.26 
92220_s_at bridging integrator 1 Bin1 -1.14 1.57 1.08 
99668_at bridging integrator 1 Bin1 -1.30 1.36 -1.15 
98066_r_at bromodomain containing 2 Brd2 2.48 1 09 -0.19 
101961 -at budding uninhibited by benzimidaz.oles 3 homolog (S. cerevisiae) Bub3 -1.33 -0.01 -1.37 
96522_at calmodulin 1 Calm1 1.20 1.60 -1.13 
93293_at calmodulin2 Calm2 1.11 -1.37 -1.17 
101040_at calpain 2 Capn2 0.51 3.11 1.67 
100610_at calpain, small subunit 1 Capns1 -0 06 0.09 1.40 
94004_at calpooin 2 Cnn2 -1.81 -5.25 1.17 
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95142_s_at capping protein (actin filament) muscle Z-line, beta Capzb -1.24 -1.35 1.09 
160106_at capping protein (actin filament), gelsolin-like Capg 1.18 1.24 1.65 
92642_at ca1:>onic alhydrase 2 Car2 2.32 6.08 1.83 
9B535_at catechol-0-methy1transferase Com! -1.45 -0.03 1.39 
160430_at catenin beta Catnb -0.07 2.08 0.04 
94831 
-
at cathepsin B Ctsb 1.13 1.70 1.64 
101019_at cathepsin C Ctsc 1.74 1.50 0.03 
101973_at Cbp/p300-interacting transactivator, with GluiAsp-rich ca'boxy-terminal dO! Cited2 -1.27 -2.08 -1.04 
92925_at CCAA T /enha'lcer binding protein (C/EBP), beta Cebpb 6.59 1.91 -1.18 
9B9BO_at C037 Mtigen Cd37 -1.17 -1.32 1.50 
103005_s_at CD44 a-�tigen Cd44 15.06 14.69 2.02 
103611_at CD47 ..-.tigen (Rh-related Mtigen, integrin-associated signal trcnsducer) Cd47 -1.61 -1.70 -1.13 
103089_at CD48 antigen Cd48 -1.57 -2.34 -1.14 
94939_at CD53 .:.-rtigen Cd53 2.05 3.14 1.62 
103016_s_at CD683"1tigen Cd68 -0.09 2.09 4.25 
94000_at COB a"'tigen, beta chain Cd8b -2.17 -4.98 -0.32 
95661 
-
at CD9wgen Cd9 1.83 2.47 1.67 
9746B_at CDC28 protein kinase 1 Cks1 -1.14 -1.99 -3.39 
103346_at CDC-like kinase 2 Clk2 -3.02 -1.58 -1.08 
102BOB_g_at CEA-related cell adhesion molecule 1 Ceacam1 5.87 12.47 3.27 
10012B_at cell division cycle 2 homdog A (S. pombe) Cdc2a -1.38 -2.50 -2.47 
1010BB_f_at cellular nucletc acid binding protein Cnbp 1.14 1.85 -0.17 
100127_at cellular retinoic acid binding protein II Crabp2 7.71 23.95 -4.61 
93595_at ceroid-lipofuscinosis, neuronal 2 Cln2 -0.08 -0.08 1.62 
160671 
-
at ceroid-lipofuscinosis, neuronal 8 Cln8 13.74 5.74 3.00 
9416B_g_at chemOkine (C-C motif) ligand 1 Ccl1 4.98 4.34 -1.62 
102736_at chemokine (C-C motif) ligand 2 Ccl2 10.44 0.17 0.13 
102424_at chemokine (C-C motif) ligand 3 Ccl3 168.87 59.04 3.08 
94146_at chemokine (C-C motif) lig<r�d 4 Ccl4 179.45 11.28 1.13 
94761 
-
at chemokine (C-C motif) ligMd 7 Ccl7 502.70 55.98 4.80 
10439B_at chemokine {C-C motif) ligand 9 Ccl9 1.71 2.60 2.32 
99413_at chemokine (C-C motif) receptor 1 Ccr1 3.98 1.52 0.24 
93697_at chromobox homolog 4 (Drosophila Pc class) Cbx4 -3.50 -2.64 -1.55 
100946_at Cluster lncl AF109906:MHC class Ill region RO gene 10.16 7.68 -2.69 
92267_at coagulation factor II (thrombin) receptor F2r 2.80 4.62 3.14 
101450_at colony stimulating factor 1 (macrophage) Csf1 19.05 4.82 2.51 
9294B_at colony stimulating factor 2 (granulocyte-macrophage) Csf2 68.07 0.08 -0.10 
9474B_g_at colony stimulating factor 2 receptor, beta 1, lOw-affinity (granulocyte--macro Csf2rb1 -0.11 1.74 2.11 
94747_at colony stimulating factor 2 receptor, beta 1, low-affinity (granulocyte-macro Csf2rb1 -1.37 1.44 1.74 
93454_at complement component 1, q subcomponent, receptor 1 C1qr1 2.24 1.56 1.23 
10172B_at complement component 5, receptor 1 C5r1 2 21 7.28 1.38 
95460_at COP9 (constitutive photomorphogenic) homolog, subunit 5 (Arabidopsis th Cops5 1.28 1.96 1.17 
93547_at core binding factor beta Cbfb -1.30 -1.30 -1.16 
102397_at core-binding factor, runt domain, alpha subunit 2: translocated to, 3 homolc Cbfa2t3h -7.25 -4.72 1.05 
94046_at c-src tyrosine kinase Csk -1 03 -3.42 1.06 
98073_at cut-like 1 (Drosophila) Cutl1 -1.00 -0.10 1.34 
94294_at cyclin 82 Ccnb2 -1 02 -2.39 -2.20 
97504_at cyclin 02 Ccnd2 -0.25 2.36 1.60 
160545_at cyclin 03 Ccnd3 -1.75 -2.02 -0.02 
160127_at cyclin G1 Ccng1 -1.51 -1.82 1.32 
9847B_at cyclin G2 Ccng2 -2.49 -3.25 -0.08 
98067_at cyclin-dependent kinase inhibitor 1A (P21) Cdkn1a 4.23 1.71 0.04 
94521 
-
at cyclin-dependent kinase inhibrtor 20 (p19, inhibits CDK4) Cdkn2d -1.37 -6.70 -2.12 
100561 
-
at cystatin B Cstb 1.46 2.21 2.31 
92608_at cysteine and glycine-rich protein 1 Csrp1 0.01 -2.40 -1.32 
100022_at cytokine inducible SH2-containing protein Cish 3.00 1.99 0.20 
103539_at cytoplasmic tyrosine kinase, Oscr28C related Tee 5.78 6.04 3.70 
10351B_at cytotoxic T lymphocyte-associated protein 2 beta Ctla2b 2.14 2.71 1.68 
93493_at DEAD (Asp-Giu-Aia-Asp) box polypeptide 5 Ddx5 -1.15 -1.79 0.13 
103250_at deafness, autosomal domirla'lt 5 homoklg (huma1) Dfna5h 1.06 2.45 0.76 
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103617_at decay accelerating factor 1 Daf1 1.23 -1.66 -0.22 
99543_s_at deoxygua'lOSine kinase Dguok -1.35 -1.90 1.20 
99905_at deubiquitinating enzyme 2 Dub2 15.36 5.22 3.16 
92BB7_at dimethyl..-ginine dimethy1aminohydrolase 2 Ddah2 0.11 -2.13 -0.13 
92730_at diphtheria toxin receptor Dtr 31.80 3.97 0.80 
96254_at OnaJ (Hsp40) homolog, subfamily B. member 1 Dnajb1 12.71 -1.22 -1.29 
10459B_at dual specificity phosphatase 1 Dusp1 26.76 2.63 1.63 
9275B_at dual specificity phosphatase 2 Dusp2 3.53 -0.18 1.06 
94522_at dynactin 3 Dctn3 1.44 1.40 1.05 
98579_at early gro.otlh response 1 Egr1 13.86 -0.10 -2.02 
102661 
-
at ea1y growth response 2 Egr2 72.53 1.81 -1.65 
9B025_at ecotropic viral integration site 2 Evi2 4.98 1.41 2.38 
9B026_g_at ecotropic viral integration site 2 Evi2 3.80 -0.01 2.06 
103342_at embryonic ectoderm development Eed -4.12 -1.24 -1.09 
100472_at enabled homolog (Drosophila) Enah -1.24 -1.77 -0.06 
99917_at enhancer of zeste homolog 2 (Drosophila) Ezh2 -1.48 -2.62 -1.76 
160857_at ephrin B2 Efnb2 4.35 3.37 0.02 
97426_at epithelial membrane protein 1 Emp1 23.55 8.57 2.53 
98525_f_at erythroid differentiation regulator edr -1.31 0.79 -1.85 
92553_at esterase 10 Es10 1.23 4.89 1.65 
9305B_at eukayotic translation initiation factor 1A Eif1a 1.95 1.61 0.17 
95046_s_at eukaryotic translation initiation factor 28, subunit 4 delta Eif2b4 -1.21 2.12 0.44 
96BB3_at euk<V)'OOc translation initiation factor 3, subunit 4 (delta) Eif3s4 -0.02 1.52 -0.12 
93089_at eukaryotic translation initiation factor 4A2 Eif4a2 -1.54 -007 -0.14 
98121 
-
at fcmesyttransferase. CAAX box, alpha Fnta -1.89 -1.43 -1 01 
98575_at fatty acid synthase Fasn -1.53 -1.44 0.12 
104017_at fatty acid-Coenzyme A ligase, long chain 4 Facl4 8.72 10.83 6.06 
160901 
-
at FBJ osteosarcoma oncogene Fos 7.79 -4.84 -1.86 
103990_at FBJ osteosarcoma oncogene B Fosb 12.96 -0.10 -1.34 
101209_at Fe receptor, lgE, high affinity I. alpha polypeptide Fcer1a -1.15 -1.27 1.15 
102337_s_at Fe receptor, lgG. low affinity lib Fcgr2b -1.65 -8.35 -0.51 
921BB_s_at feline sew-coma oncogene Fes -1.11 -2 04 -1.33 
92587_at ferredoxin 1 Fdx1 2.29 -2.11 -1.20 
99872_s_at ferritin light chain 1 Ftl1 1.40 1.57 1.22 
97949_at fibrinogen-like protein 2 Fgl2 1.20 2.98 2.03 
99546_at FK506 binding protein 2 Fkbp2 -116 -1.35 -1.45 
92809_r_at FK506 binding protein 4 Fkbp4 -1.75 -2.01 -1.59 
97327_at flap structure specific endonuclease 1 Fen1 -2.94 -2.35 -1.97 
100515_at turin (paired basic amino acid cleaving enzyme) Furin 2.05 1.30 1.25 
100133_at Fyn proto-oncogene Fyn 1.87 4.09 1.20 
104333_at G7e protein G7e-pending -2.05 -8.53 -2.19 
94192_at ga�gliosid&induced differentiation-associated-protein 10 Gdap10 -1.61 1.58 0.13 
102654_at GAT A binding protein 1 Gata1 -1.54 -1.50 -1.09 
102789_at GAT A binding protein 2 Gata2 -2.70 -1.31 -1.11 
93750_at gelsolin Gsn 1.75 2.30 1.80 
94295_at general transcription factor II I Gtf2i -1.57 -1.33 -1.05 
92655_at glucosaninyl (N-acetyl) transferase 1, core 2 Gcnt1 1.78 -0.07 0.27 
100573_f_at glucose phosphate isomerase 1 Gpi1 0.12 -1.45 -1.52 
99649_at glutamate-cysteine ligase, catalytic subunit Gclc 1.90 1.39 -1.35 
94897_at glutathione peroxidase 4 Gpx4 1.03 -1.41 1.20 
99583_at glutathione S-tra1sferase. pi 2 Gstp2 -1.21 -1.43 -1.27 
97525_at glycerol kinase Gyk 1.62 1.80 0.31 
9B984_f_at glycerol phosphate dehydrogenase 2, mitochondrial Gpd2 1.75 0.04 -0.06 
101620_at glycoprotein 1 b, alpha polypeptide Gp1ba -1 22 -2.96 -1.65 
92611 
-
at GPI-anchared membrane protein 1 Gpiap1 -1.57 -1.10 -0.13 
102877_at granzymeB Gzmb 1.42 0.13 1.16 
102313_at GTP cyclohydrolase 1 Gch 5.99 2.52 0.12 
100514_at gu<W'line nucleotide binding protein, alpha 13 Gna13 2.08 1.21 1.13 
95364_at guanine nucleotide binding protein, alpha 14 Gna14 -2.17 -13.93 0.11 
t60114_at guanosine diphosphate (GOP) dissociation inhibitor 3 Gdi3 -1.26 -1.32 0.00 
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95419_at H1 histonefcrnily, memberO H1f0 0.54 -2 12 -1.60 
93019_at H2A histone family, member X H2afx 0.41 -1.43 -1.75 
101954_at H2A histone family, member Z H2afz 1.05 0.00 -1.43 
100708_at H3 histone, family 38 H313b 2.87 -0.02 -1.33 
95282_at heat shock protein 1, alpha Hspca -1.09 -0.06 -1.68 
98111 
-
at heat shock protein 105 Hsp105 -1.37 2.36 -1.68 
93875_at heat shock protein 1A Hspa1a 9.16 8.78 1.79 
93276_at hematological and neurological expressed sequence 1 Hn1 -1.23 -2.03 -1.29 
160101 
-
at heme oxygenase (decycling) 1 Hmox1 4.12 2.23 -0.24 
102410_at hepa"an sulfate (glucoscmine) �0-sulfotransferase 1 Hs3st1 12.22 10.55 2.19 
92629_f_at hepatoma-derived growth factor Hdgf -1.28 -1.36 -1.21 
93117_at heterogeneous nuclea- ribc:w1ucleoprotein A2JB1 Hnrpa2b1 -1.34 -1.23 -0.23 
93095_at high mobility group box 1 Hmgb1 -0.29 -1.55 -1.46 
93250_r_at high mobility group box 2 Hmgb2 -1.14 -3.70 -1.97 
98038_at high mobility group box 3 Hmgb3 -1.26 -1.81 -2 07 
101589_at high mobility group nucleosomal binding domain 2 Hmgn2 -1.52 -1.93 -1.77 
93328_at histidine decart>oxylase Hdc 21.56 29.13 2.48 
99581 
-
at histidine triad nucleotide binding protein Hint -1.25 -1.23 -0.07 
101886_f_at histocompatibility 2, D regton locus 1 H2-D1 -0.02 1.10 1.50 
97540_f_at histocompatibility 2, D region locus 1 H2-D1 0.01 -1 02 125 
99379_f_at histocompatibility 2, K region H2-K -0.02 1.13 1.41 
99378_f_at histocompatibility 2, Q region locus 1 H2-Q1 0.21 1.35 1.78 
t01876_s_at histocompatibility 2, T region locus 17 H2-T17 -1.39 1.24 1.65 
94288_at histone 1, H1c Hist1h1c 11.30 0.99 0.93 
93833_s_at histone 1, H2bc Hist1h2bc 10.00 5.04 2.45 
160176_at histone cell cycle regulation defective interacting protein 5 Hirip5 -1.44 -1.65 1.05 
96416_f_at histooe1, H3d Hist1h3d 2.32 1.47 -0.39 
97809_at HLA-B associated transcript 8 BatS -1.25 -1.46 1.23 
160384_at HLA-S.associated transcript 1A Bat1a -1.46 -1.22 -1.40 
103262_at homeOOomain interacting protein kinase 1 Hipk1 35.53 10.46 3.95 
103833_at homeodomain interacting protein kinase 2 Hipk2 -1.03 8.29 1.15 
101096_s_at HS1 binding protein Hs1bp1 1.26 1.69 -2.64 
160451 
-
at hypothetical protein MGC18745 MGC18745 2.12 1.86 0.00 
t60107_at hypoxanthine guanine phosphoribosy1 tra'lsferase Hprt -1.10 -1.50 -1.33 
104500_at iduronidase, alpha-L· ldua -1.77 -2.15 -0.14 
99109_at immediate early response 2 ler2 1.96 -0.64 -2.38 
94384_at immediate ea'ly response 3 ler3 1.71 0.23 0.49 
100380_f_at immunoglobulin heavy chain 4 (serum lgG1) lgh-4 -1.72 -6.39 -2.01 
100682_f_at immunoglobulin kappa chain variable 8 (VB) lgk-VB -2.00 -4.91 -1.55 
100277_at inhibin beta-A lnhba 3.80 0.22 0.19 
93013_at inhibitor of DNA binding 2 ldb2 0.03 1.65 1.47 
100578_at inosine 5'-phosphate dehydrogenase 2 lmpdh2 -1.43 -1.56 -1.56 
101441 _i_at inositol1 ,4,5-triphosphate receptor 5 ltpr5 -1.21 -1.40 -1.08 
94398_s_at inositol polyphosphate-S..phosphatase 8 lnpp5b -1.70 -1.53 1.23 
102884_at inositol polyphosphate-S..phosphatase 0 lnpp5d -1.24 -1.70 0.09 
100566_at insuli�like growth factor binding protein 5 lgfbp5 -1.32 2.33 1.57 
101123_at integral membrcwle protein 28 ltm2b -1.21 -1.40 1.11 
t02353_at integrin bets 2 ltgb2 0.35 3.50 1.66 
100906_at integrin beta 7 ltgb7 -1.24 -1.47 0.05 
160092_at interferon-related developmental regulator 1 lfrd1 10.44 1.51 0.50 
103486_at inter1eukin 1 beta 111b 11.89 7.08 1.68 
98500_at inter1eukin 1 receptor-like 1 111rl1 -1.09 -1.23 1.18 
98501_at interleukin 1 receptor-like 1 ll1rl1 5.04 4.10 0.19 
94168_at interteukin 13 1113 95.52 18.27 -0.05 
99991 
-
at interleukin 17 receptor 1117r 2.34 -0.24 1.29 
101144_at interteukin 18 recept()( 1 1118r1 -2.29 -2.62 0.37 
92283_s_at interleukin4 114 15.23 1.74 1.04 
102021 
-
at interteukin 4 receptor, alpha 114ra -2.22 -1.41 0.09 
102218_at interleukin 6 116 14.27 3.26 0.08 
93029_at isocitrate dehydrogenase 3 (NAD+), gamma ldh3g -0.18 -1.36 1.15 
102364_at Jun proto-oncogene related gene d1 Jund1 2.97 1.30 -0.03 
102362_i_at Ju�B oncogene Junb 22.14 2.41 1.19 
1 02363 _r _at Jun-B oncogene Junb 4.50 0.46 0.03 
99541 
-
at kinesin family member 11 Kif11 -1.76 -2.90 -2.74 
97991 
-
at Kirsten rat sarcoma oncogene 2, expressed Kras2 4.09 -1.44 -0.01 
99958_at kit oncogene Kit -1.47 -1.41 1.36 
98059_s_at la'nin A Lmna 2.01 1.35 -1.15 
98065_at latexin Lxn 1.13 1.46 1.69 
95706_at lectin, galactose binding, soluble 3 Lgals3 2.16 5.27 2.78 
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103335_at lectin, galactose binding, soluble 9 Lgals9 0.01 -2.03 0.07 
93600_at leptin receptor gene-related p.-otein Obrgrp -1.40 -1.81 1.31 
100540_at leukotriene A4 hydrolase Lla4h -1.14 -1.37 -1.16 
93930_at UM and SH3 protein 1 Lasp1 11.67 22.05 6.61 
98122_at UM domain only4 Lmo4 -1.35 -3.91 -1.76 
93078_at lymphocyte CW'Itigen 6 comptex. locus A Ly6a -1.19 -1.69 -1.31 
101487_f_at lymphocyte antigen 6 complex. locus E Ly6e 1.15 -0.03 -2.01 
98000_at lymphocyte antigen 64 Ly64 -0.29 -1.76 -1.30 
102957_at lymphocyte cyt:osolic protein 2 Lcp2 1.69 -1.12 0.01 
160089_at lysosomal membrane glycoprotein 1 Lamp1 1.02 -1.11 -1.32 
AFFX-Murll4_at M25892 Mus musculus interleukin 4 (11-4) mRNA 4.12 0.14 0.06 
94805_f_at M33988:histone H2A.1 gene -1.40 -2.38 -2.21 
97719_at macrophage stimulating 1 receptor (c-met-related tyrosine kinase) Mst1r 9.66 -0.53 -1.99 
92216_at MAD homolog 7 (Drosophila) Madh7 5.53 0.85 1.11 
99632_at MAD2 (mitotic CWTeSt deficient, homolog)-like 1 (yeast) Mad211 -1.55 -2.37 -3.10 
101082_at malic enzyme, supernatant Mod1 -1.34 5.89 1.10 
160580_at mannosldase 1. apha Man1a 3.71 2.59 1.81 
97203_at MARCKS-Iike protein Mlp 19.94 2.21 -0.09 
99024_at Max dimerization protein 4 Mad4 -1.34 -0.10 1.59 
103488_at meiosis-specific nuclear structural protein 1 Mns1 -2.12 -9.39 -1.29 
96767_at membrane bound C2 domain containing protein Mbc2 -1.17 -1.80 -1.17 
96509_at membrane-spaming 4-domains, subfanily A. member 2 Ms4a2 -0.28 -4.29 1.80 
93573_at metallexhionein 1 Mt1 2.76 -0.10 0.03 
104340_at methyi-CpG binding domain protein 1 Mbd1 -2.55 -0.06 -1.15 
102161_f_at MHC (Qa) 02-k gene for class I altigen X58609 0.04 1.21 1.62 
100062_at minichromosome maintenance deficient 3 (S. cerevisiae) Mcm3 -1.43 -2.79 -1.70 
93041 
-
at minichromosome maintenance deficient 4 homolog Mcm4 -1.66 -2.14 -1.93 
100156_at minichromosome maintenance deficient 5, cell division cycle 46 Mcm5 -1.69 -2.49 -1.86 
93358_at minichromosome maintenance deficient 7 (S. cerevisiae) Mcm7 -1.68 -3.45 -1.97 
93314_g_at mitogen activated protein kinase kinase 3 Map2k3 2.40 2.39 1.21 
96632_at mortality factor 4 like 2 Morf412 1.73 1.57 -1.18 
92644_s_at myeloblastosis oncogene Myb -2.81 -0.07 1.05 
160463_at myeloid differentiation pfimary response gene 116 Myd116 3.37 1.50 1.25 
96285_at myeloid-associated differentiation ma?;er Myadm -1.14 -2.07 -1.11 
92400_at N-deacetylase/N-sulfotrCI'lsferase (hep<r"an glucos<minyl) 2 Ndst2 -2.62 -2.80 1.09 
102780_at neoplastic progression 3 Npn3 62.79 11.95 0.63 
101469_at neural precursor cell expressed, developmentally do.Yn-regulated gene 9 Nedd9 5.92 2.01 0.14 
93101 _s_at neural precur:ior cell expressed, developmentally down-regulled gene 4 Nedd4 -0.12 -2.04 -0 02 
103048_at neuroblastoma myc-related oncogene 1 Nmyc1 4.12 1.22 -1.21 
103662_at neutrophil cytosolic factor 4 Ncf4 -1.31 -1.88 1.67 
100962_at Ngfi-A binding protein 2 Nab2 12.49 2.54 -0.89 
103805_at nibrin Nbn -1.54 -5.91 -1.55 
98114_at Niem<r"m Pick type C 1 Npc1 1.43 1.11 1.16 
160464_s_at N-myc downstrean regulated 1 Ndr1 12.81 4.67 -0.05 
96596_at N-myc dovtnstream regulated-like Ndrl 12.56 4.94 0.04 
95380_at non MHC restricted killing associated Nmrk 2.23 1.95 1.59 
102209_at nuclea' factord activated T-eens. cytoplasmic 1 Nfatc1 7.55 2.54 1.41 
98427_s_at nuclear factor of kappa light chain gene enha'ICer in B-cells 1, p105 Nfkb1 1.56 -1.47 -0.01 
98010_at nuclear factor, erythroid derived 2 Nfe2 -7.34 -0.98 -0.02 
102955_at nuclear factor, interleukin 3, regulated Nfil3 6.90 2.58 -3.87 
99564_at nuclear protein 95 Np95 -1.58 -4.20 -1.87 
103288_at nucl&a" receptor interacting protein 1 Nrip1 2.17 1.75 1.71 
102371 
-
at nuclear receptor subfcmily 4, group A, member 1 Nr4a1 37.89 -1.78 1.40 
92248_at nuclear receptor subfamily 4, group A, member 2 Nr4a2 31.69 2.22 2.54 
92249_g_at nuclea' receptor subfamily 4, group A, member 2 Nr4a2 15.58 2.22 1.13 
102197_at nudeobindin 2 Nucb2 -1.38 2.32 1.49 
100144_at nucleolin Ncl -1.25 0.07 -1.59 
94372_at nudix (nucleoside diphosphate linked moiety X)-type motif 1 Nudt1 -1.54 -2.28 -1.33 
99019_at P450 (cytochrome) oxidoreductase Par 0.08 1.79 1.23 
100328_s_at paired-lg-like receptor A3 Pira3 1.44 0.80 3.74 
98003_at paired-lg-llke receptor B Pirb 0.00 1.16 2.41 
95491 
-
at Par1<.inson disease (autosomal recessive, early onset) 7 Park? -1.12 -1.53 -1.94 
96128_at PCT AIRE-mot.if protein kinase 3 Pctk3 2.43 2.17 1.26 
101700_at per-hexamer repeat gene 4 Phxr4 6.59 1.61 1.36 
97758_at peroxiredoxln 1 Prdx1 1.70 3.70 -1.13 
96258_at peroxiredoxin 3 Prdx3 -1.19 -1.39 -0.03 
93495_at peroxiredo>cin 4 Prdx4 1.11 0.02 -1.72 
92637_at phosphofructokinase, liver, 8-type Pfkl 0.04 -2.44 -1.84 
93346_at phOsphOglycerate kinase 1 Pgk1 0.24 0.33 -2.92 
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100607_at phospholipase 03 Pld3 -1.13 1.62 2.08 
102839_at phospholipid scramblase 1 Plscr1 5.03 2.25 1.46 
101027 _s_at pituitary tumor-tra1sforming 1 Pttg1 -1.11 -1.49 -0.27 
94932_at platelet derived growth factor, alpha Pdgfa 2.98 7.12 2.88 
160829_at pleckstrin homology-like dcmain, fcmily A, member 1 Phlda1 7.99 1.46 -1.35 
100720_at poly A binding protein, cytoplasmic 1 Pabpc1 0.17 1.54 1.47 
103207_at polymerase (DNA directed), alpha 1 Pola1 -1.39 -2.53 -0.43 
101461_f_at praja1. RING-H2 motif containing Pja1 -1.46 -1.19 0.01 
100606_at prion protein Prnp -0.46 -3.58 1.11 
101881 _g_at proc:ollagen, type XVIII, alpha 1 Col18a1 -1.25 25.28 10.55 
101585_at progesterone receptor membrale component 1 Pgnnc1 -0.13 -1.31 -1.37 
103029_at progral'lmed cell death 4 Pdcd4 1.30 -1.97 1.27 
98858_at programmed cell death 8 Pdcd8 -1.31 -1.34 -1.25 
101065_at proliferating cell nuclear GW'ltigen Pcna 1.67 -1.34 -1.67 
101468_at properdin factor, complement Pte 1.24 1.02 -1.78 
96588_at prostagl�in E receptCX' 3 (subtype EP3) Ptger3 -1.51 -2.33 -0.12 
104647_at prostaglaldin-endoperoxide synthase 2 Ptgs2 93.16 1.80 -1.12 
100733_at proteasome (prosome. macropain) subunit, alpha type 2 Psma2 1.00 1.40 -0.05 
92544_f_at p(Qteasome (prosome, mac:ropain) subunit, alpha type 3 Psma3 -1.01 1.54 -0.01 
10155B_s_at proteasome (prosome. macropain) subunit, beta type 5 Psmb5 -1.19 1.75 0.28 
94263_f_at l)(oteasome (prosome, macropain) subunit, beta type 7 Psmb7 -1.00 1.52 -1.57 
99510_at protein kinase C. beta Prkcb -1.24 -1.37 1.19 
104531 _at protein kinase C. delta Prkcd -1.51 -1.50 1.19 
160698_s_at protein kinase C. delta Prkcd -1.57 -1.41 1.11 
103559_at protein kinase, cAMP dependent, catalytic, alpha Prkaca -1.03 -1.37 0.03 
93116_at protein kinase, cAMP dependent, catalytic. beta Prkacb -1.34 -1.08 1.09 
101482_at protein phosphatase 1, catalytic subunit, gamma isoform Ppp1cc -1.97 -1.35 -1.25 
94929_at protein tyrosine phosphatase, non-receptor type 1 Ptpn1 -1.13 1.60 0.17 
101996_at protein tyrosine phosphatase, non-receptor type 2 Ptpn2 -1.86 -4.99 -1.80 
92358_at protein tyrosine phosphatase, non-receptor type 8 Ptpn8 40.28 8.13 -1.06 
100976_at protein tyrosine phosphatase, non-receptor type 9 Ptpn9 -1.43 -1.71 0.04 
10129B_g_at protein tyrosine phosphatase, receptor type, C Ptprc 1.73 2.12 2.34 
99478_at protein tyrosine phosphatase, receptor type, C polypeptid&associated prot• Ptprcap 1.06 1.53 1.59 
93323_at proteolipid protein 2 Plp2 0.13 1.37 1.36 
102791 -at proteosome (prosome, macropan) subunit. beta type 8 (la--ge multifunction Psmb8 -1.20 -1.77 -0.06 
100718_at prothymosin alpha Ptma 0.03 -1.12 -1.54 
101926_at proviral Integration site 2 Pim2 -1.36 -3.68 -2.77 
95586_at purinergic receptor P2X. ligand-gated ion chwmel 4 P2rx4 -1.88 -3.41 1.28 
97415_at RAB3D, member RAS oncogene family Rab3d -1.33 -5.71 -0.14 
101921 -at RAB4A, member RAS oncogene faTlily Rab4a 6.56 8.42 4.47 
104108_at Rab6 interacting protein 1 Rab8ip1 -0.26 -2.28 0.16 
95785_s_at RAB7, member RAS oncogene faTlily Rab7 3.93 3.23 2.77 
95516_at RA89, member RAS oncogene family Rab9 -1.64 -1.60 0.11 
94768_at RAD21 homdog (S. pombe) Rad21 -1.15 -2.31 -1.41 
98573_r_at RAN binding protein 1 Ranbp1 -1.51 -1.29 -1.61 
101254_at RAN, member RAS oncogene family Ran -1.25 0.03 -1.47 
102028_at Ras association (RaiGDSIAF-6) domain faTlily 5 Rassf5 2.59 1.82 1.30 
101030_at ras homolog gene faTlity, member AB Arhb 6.12 2.39 1.12 
93319_at RAS p21 protein activator 3 Rasa3 -1.67 -1.75 1.15 
101584_at Ras suppressor protein 1 Rsu1 0.00 -1.49 1.16 
103642_at Ras-GTPase-activating protein SH3-domain binding protein G3bp-pending -1.14 0.05 -1.43 
102821 _s_at RAS-Iike, family 2, locus 9 Rasl2-9 -1.21 0.05 -1.64 
97319_at Ras-related associated 'Nith diabetes Rrad 7.27 1.47 1.17 
98950_at Ras-related GTP binding C Rragc -1.13 -1.29 1.11 
102300_at receptor-associated protein of the synapse Rapsn 1.25 -2.03 -2.25 
94378_at regulator of G-protein signaling 16 Rgs16 6.06 3.09 1.36 
97844_at regulator of G-protein signaling 2 Rgs2 12.87 2.62 1.59 
97948_at retinoblastoma 1 Rb1 -1.30 -2.68 -0.10 
92647_at retinoblastoma binding protein 4 Rbbp4 -1.38 -1.67 -1.34 
93081 -at retinoblastoma binding protein 7 Rbbp7 -1.39 0.06 -1.87 
98434_at Rho guanine nucleotide exchange factor (GEF7) Arhgef7 -1.28 2.17 1.56 
100612_at ribonucleotide reductase M 1 Rnn1 -1.64 -5.05 -2.42 
98007_at ribosomal protein S6 kinase, polypeptide 2 Rps6ka2 2.81 6.15 1.67 
96785_at RIKEN eDNA 0610013004 gene 0610013D04Rik -8.56 -4.76 0.08 
160205_f_at ring finger protein 11 Rnf11 1.36 1.99 1.21 
101965_at ring finger protein 13 Rnf13 -0.22 -2.91 0.12 
92539_at S100 calcium binding protein A10 (calpactin) S100a10 1.30 1.54 1.72 
98600_at 5100 calcium binding protein A 11 (caHzzain) S100a11 1.32 2.44 2.82 
1 00960 _g_ at S100 calcium binding protein A 13 S100a13 -1.10 1.02 1.42 
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100959_at 5100 cak:ium binding protein A13 S100a13 -1.29 1.04 1.30 
92770_at $100 calcium binding protein A6 (calcyclin) S100a6 -1.18 0.05 1.59 
96024_at S-adenosyihoolocysteine hydrolase A hey -1.24 -2.09 -1.57 
103080_at SAM doman and HO domain, 1 Samhd1 3.10 0.12 1.75 
92471 _i_at schlafen 2 Slfn2 -3.34 -1.79 1.56 
92472_f_at schlafen 2 Stfn2 -6.02 -1.75 1.40 
92636_f_at SEC61, gamma subunit (S. cerevisiae) Sec61g 0.03 1.10 -1.24 
97519_at secreted phosphoprotein 1 Spp1 11.95 29.72 2.52 
103468_at selectin, platelet (p-selectin) lig<Wld Set pi -1.01 -1.44 0.02 
160836_at sema domain, immunoglobulin domain {lg), transmembrEW"Je domain (TM) < Sema4d -1.11 -1.51 1.03 
101995_at sequestosome 1 Sqstm1 1.99 1 .49 1.34 
102860_at serine (or cysteine) proteinase inhibitor, clade A, member 3G Serpina3g 1.43 -2.27 -1.40 
92978_s_at serine (or cysteine) proteinase inhibftor, clade B. member 2 Serpinb2 2.66 1.62 0.21 
96060_at serine (or cysteine) proteinase inhibitor, clade B. member 6a Serpinb6a -1.13 1.46 1.93 
94147_at serine (or cysteine) proteinase inhibitor. clade E. member 1 Serpine1 10.71 2.43 0.21 
93680_at serine/threonine kinase 10 Stk10 -2.51 -1.74 -0.03 
93272_at serin&'t.lveooine kinase 16 Stk16 -1.92 -1.22 0.06 
92639_at serine/threonine kinase 6 Stk6 -1.92 -5.38 -3.38 
99847_at sialyitransferase 4A (beta-galactoside alpha-2,3-sialytransferase) Siat4a 3.16 3.86 -0.07 
102318_at sialyttransferase 8 (alpha-2. 8-sialyttransferase) 0 Siat8d -9.91 -8.09 -0.25 
101519_at signal recognition pa1icte 14 Srp14 0.00 1.48 1.08 
102994_at signal transducer and activator of transcriptia"'4 Stat4 -1.23 -2.21 1.11 
97421 
-
at SMC2 structural maintena1ee d chromosomes 2-like 1 (yeast) Smc211 -1.41 -7.89 -1.96 
92582_at solute caTier fanily 1, member 7 Slc1a7 1.65 2.43 -0.28 
99133_at solute carrier family 3 (activators of dibasic and neutral amino acid tr2r1spo S\c3a2 1.51 0.11 -1.35 
104221 
-
at solute ca-rier family 7 (cationic amino acid transporter, y+ system), membe Slc7a5 2.74 2.63 -2.72 
97243_at solute Ca"rier family 9 (Sodium/hydrogen excha-�ger), isoform 3 regulator 1 S\c9a3r1 -1.09 -1.44 1.15 
160543_at sorting nexin 3 Snx3 -1.19 -1.66 -1.16 
92540_f_at spermidine synthaSe Srm -1.43 0.19 -1.41 
94017_s_at splicing factor, a-ginin&'serine-rich 2 (SC-35) Sfrs2 -1.15 -0.01 -1.61 
99876_at src-like adaptor Sta 15.77 1.24 0.17 
94057_g_at stea-oyl-Coenzyme A desaturase 1 Scd1 1.56 2.48 1.96 
94056_at stea-O'ft-Coenzyme A desaturase 1 Scd1 1.27 2.20 1.61 
95758_at stearoyi-Coenzyme A desaturase 2 Scd2 -1.49 -0.05 1.19 
160471 _at stem-loop binding protein Slbp -2.64 -2.65 -0.28 
103421_at stromal cell derived factor receptor 2 Sdfr2 -1.06 2.67 1.41 
160428_at succinate-Coenzyme A ligase, GOP-forming, beta sublU1it Suclg2 -1.15 -2.00 -1.49 
92232_at suppressor of cytol<.ine signaling 3 Socs3 12.37 0.12 1.34 
92855_at suppressor of initiator codon mutations, related sequence 1 (S. cerevisiae) Sui1-rs1 2.36 1.59 0.03 
100499_at syntaxin 3 Stx3 -1.77 -2.14 -0.04 
101398_at syntaxin binding protein 2 Stxbp2 -1.32 -1.85 -0.01 
99448_at tal in Tin 0.07 0.19 1.28 
92339_at TATA box binding protein (Tbp)-associated factor, RNA polymerase I, A Taf1a 5.84 3.19 1.35 
97973_at T -<:ell acute lymphocytic leukemia 1 Ta\1 -1.24 1.14 1.13 
102744_at T -cell receptor gamma. variable 2 Tcrg-V2 -2.12 -77.03 -3.01 
102745_at T -cell receptor gamma, variable 4 Tcrg-V4 -1.54 -22.55 -1.69 
101551 _s_at testis derived transcript Tes 1.16 1.84 1.42 
101502_at TG interacting factor Tgif 3.92 -1.82 1.63 
99602_at TGFB inducible ea1y grONth response 1 Tieg1 3 .16 1.35 1.14 
99603_g_at TGFB inducible early growth response 1 Tieg1 5.96 3.25 1.08 
92807_at thioredoxin 1 Txn1 -0.01 1.43 -1.56 
99985_at thioredoxin reductase 1 Txnrd1 2.00 3.35 -0.16 
95694_at topoisomerase (DNA) I Top1 1.26 -1.92 -1.28 
101959_r_at trarlscription factor Dp 1 Tfdp1 -1.97 -2.12 -1.39 
93789_s_at tr<r"lscriptional regulator, SIN38 (�t) Sin3b 1.62 3.22 1.11 
104623_at trcrlsducin-like enhancer of split 3, homolog of Drosophila E(spl) Tte3 -0.04 2.38 1.07 
AFFX-TransRecMur/X57349_M_at tralsfenin receptor Trfr 7.97 15.08 -0.12 
101918_at transforming growth factor. beta 1 Tgfb1 1.56 2.31 1.19 
103035_at trarlsporter 1, ATP-binding cassette, sub-fa'Tlily 8 (MDRfTAP) Tap1 -1.42 -2.53 1.20 
t02873_at transporter 2, ATP·binding cassette, sub-family 8 (MDRITAP) Tap2 -1.40 -1.82 1.13 
99566_at triosephosphate isomerase Tpi 0.33 -1.89 -2.61 
93071 
-
at tripatte motif protein 28 Trim28 -1.65 -1.38 -1.40 
160532_at tropomyosin 1, alpha Tpm1 1.70 1.85 0.07 
99972_at tryptopha1 hyd�e 1 Tph1 -0.22 -2.20 1.03 
102308_at tubby-like protein 3 Tulp3 -1.43 -1.70 -0.07 
100342_i_at tubulin. alpha 1 Tuba1 -1.09 -1.67 0.00 
100343_f_at tubulin, alpha 1 Tuba1 -1.02 -1.59 -1.27 
98759_f_at tubulin, alpha 2 Tuba2 1.11 -1.57 -1.42 
94835_f_at tubulin, beta 2 Tubb2 -1.33 -1.41 1.10 
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94788_t_at tubulin. beta 5 TubbS -1.36 -1.96 -1.24 
94789_r_at tubulin, beta 5 TubbS -1.17 -1.89 -1.26 
100151 -at tumor differentially expressed 1 Tde1 -1.11 -2.27 1.08 
102629_at tumor necrosis factor Tnt 16.99 2.99 0.80 
101136_at tumor necrosis factor (ligand) superfamily, member 8 Tnfsf8 S.S1 1.34 0.46 
92415_at tumor necrosis factor (�ga1d) superfamily, member 9 Tnfsf9 3.44 -0.01 1.36 
94928_at tumor necrosis factor receptOf superfamily, member 1b Tnfrsf1b 1.66 2.10 -0.4S 
99392_at tumor necrosis factor, alpha-induced protein 3 Tnfaip3 1.91 7.76 3.9S 
160499_at tumor rejection antigen gp96 Tra1 -1.26 -1.44 -1.42 
104679_at TXK tyrosine kinase Txk 1.34 -1.71 1.64 
93908_f_at type liB intracisternal A-pa1icle (lAP) element encoding integrase X16670 2.00 1.74 1.84 
AFFX-MURINE_b1 -at U01310 Mus musculus C57/Biack6 BC1 scRNA -1.S2 -1.16 -1.46 
92217_s_at U05265:Giycoprotein 49 B 2.20 1.39 1.34 
101255_at ubiquitin 8 Ubb 1.S8 1.13 1.08 
95215_t_at ubiquitin C Ubc 1.9S 1.S9 1.28 
96695_at ubiquitin-conjugating enzyme E2A, RAD6 homolog (S. cerevisiae) Ube2a 1.68 -1.28 1.16 
95703_at ubiquitin-like 1 (sentlin) activating enzyme E1A Uble1a -1.SS -1.86 -1.24 
103002_at UDP-Gal:betaGicNAc beta 1.4· galactosyltransferase, polypeptide 1 B4galt1 1 01 1.66 1.40 
97934_at UOP-N-acetyl-alpha-0-galactosamine:polypeptide N-acetylgalactosaminylb Galnt1 -1.38 -1.83 -1.09 
95555_at unc119 homolog (C. elegans) Unc119h -1.23 -4.17 0.00 
94381 -at uridine monophosphate kinase Umpk -2.23 -1.6S 0.10 
103520_at vasculcw endothelial growth factor A Vegfa 4.00 1.42 -0.83 
93305_t_at vesicle-associated membrcne protein 8 VampS -1.47 -1.61 1.02 
100302_at v-maf musculoaponeurotic fibrosa"coma oncogene family, protein F (avian) Maff 6.89 -0.10 2.92 
102919_at v-maf musculoaponeurotic fibrosarcoma oncogene family, protein K (avian: Mafk 2.88 2.14 0.17 
101458_at wee 1 homolog (S. pombe) Wee1 1.64 0.14 0.10 
92262_at wild-type p53-induced gene 1 Wig1 -1.79 -0.16 1.40 
1 00522_s_at WW domain binding protein 5 WbpS 0.06 -1.61 -1.42 
AFFX-18SRNAMur/X00686_5_at X00686:gene for 18S rRNA -1.19 -1.S6 -1.83 
93909_f_at X04120:1ntracistemal A particles, Thbd linked 2.24 2.08 0.89 
96657_at X58609:Mouse MHC (Qa) 02-k gene f()( class I Mtigen Sat 4.4S 1.87 1.83 
160321 -at zinc finger protein 216 Zfp216 3.03 1.S7 -0.01 
92409_at zinc finger protein 260 Zfp260 -4.18 -4.S9 -0.72 
99001 -at zinc finger prolein 292 Zfp292 -2.48 -1.08 -1.30 
93324_at zinc finger protein 38, C3H type-like 1 Zfp3611 4.33 -1.27 1.29 
102293_at zinc finger protein, subfanily 1A, 1 (lka'os) Znfn1a1 2.2S 3.91 2.SS 
100046_at Mthfd2 -1 01 -0.82 -1.89 
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94788_f_at tubulin. beta 5 Tubb5 -1.36 -1.96 -1.24 
94789_r_at tubulin, beta 5 Tubb5 -1.17 -1.89 -1.26 
100151 -at tumor differentially expressed 1 Tde1 -1.11 -2.27 1.08 
102629_at tumor necrosis factor Tnf 16.99 2.99 0.80 
101136_at tumor necrosis factor (lig<r�d) supertamily, member 8 Tnfsf8 5.51 1.34 0.46 
92415_at tumor necrosis factor (Hgand) superfamily, member 9 Tnfsf9 3.44 -0.01 1.36 
94928_at tumor necrosis factor receptor superfanily, member 1b Tnfrsf1b 1.66 2.10 -0.45 
99392_at tumor necrosis factor, alpha-induced protein 3 Tnfaip3 1.91 7.76 3.95 
160499_at tumor rejection antigen gp96 Tra1 -1.26 -1.44 -1.42 
104679_at TXK tyrosine kinase Txk 1.34 -1.71 1.64 
93908_f_at type liB intracisternal A-particle (lAP) element encoding integrase X16670 2.00 1.74 1.64 
AFFX-MURINE_b1 -at U01310 Mus musculus C57/Biack6 BC1 scRNA -1.52 -1.16 -1.46 
92217_s_at U05265:Giycoprotein 49 B 2.20 1.39 1.34 
101255_at ubiquitin B Ubb 1.58 1.13 1.08 
95215_f_at ubiquitin C Ubc 1.95 1.59 1.28 
96695_at ubiquitin..conjugating enzyme E2A, RAD6 homolog (S. cerevisiae) Ube2a 1.68 -1.28 1.16 
Qt\70� ::��t ,,...,;,..,,;tj,.._ijlto1fc:.,...,lrin\,...-tiv::atii"V''61"1...,...., S:16 llhl�1 � -1 "" -1 A� -1 ?.d. 
VITA 
171 
